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ABSTRACT 
Background: Breast and gynaecological cancers are the leading causes of cancer morbidity and 
mortality among women in developing countries. Advanced stage diseases with limited 
availability for treatment imply significant symptom burden; the relief of which poses a 
challenge for the health care providers.   
Aim: This study was conducted to measure symptom burden and relief among breast and 
gynaecological cancer patients accessing care in a tertiary health institution in Nigeria. 
Objectives : 1)To determine the prevalence of symptoms among breast cancer and 
gynaecological cancer patients accessing care in UITH, Ilorin; 2) To determine the most 
distressing symptoms experienced by breast and gynaecological cancer patients accessing care in 
UITH, Ilorin and 3) To assess symptom relief in the two studied groups. 
Methods: Both inpatients and outpatients with breast and gynaecologic cancers accessing care 
during the study period were recruited. All patients completed an interviewer administered 
MSAS-SF which assesses a 7-day prevalence and distress/frequency of 32 
physical/psychological symptoms. Symptom relief was assessed 7 days later. Demographics, 
cancer stages, treatments received and palliative care referrals were obtained from the case notes. 
Karnofsky Performance Status Scale was used to assess functional status. 
Results: Fifty breast and 49 gynaecological cancer patients were studied. Eighty percent of breast 
cancer and 91.9% of gynaecological cancer patients had advanced cancer. The overall mean 
number of symptoms was 5.8 + 4.5 for breast cancer while gynaecological cancers had 8.1 + 4.6. 
The top 5 symptoms in breast cancer patients were pain (62%), worrying (44%), feeling sad 
(42%), weight loss (40%) and difficulty sleeping (38%). Gynaecological cancers had weight loss 
(67.3%), pain (65.3%), worrying (53.1%), feeling sad (51.0%) and lack of energy (46.9%) as the 
top 5. The most distressing symptoms were cancer-site specific such as fungating breast masses 
in breast cancer patients and vaginal bleeding/discharges in gynaecological cancer patients. Both 
groups similarly had pain and “don’t look like myself” as most distressing too. Symptoms reliefs 
were poor and comparable between the two groups and palliative care referrals were also 
generally low but worse among breast cancer patients. Gynaecological cancer patients had higher 
Global Distress Index (GDI= 0.88 Vs 0.48), were more physically distressed (MSAS-PHYS= 
viii 
0.67 Vs 0.40) and had a poorer KPS (77 + 17.41 Vs 85 + 16.91) compared to breast cancer 
patients. 
Conclusions:  This study shows higher symptom burden in gynaecological cancer patients, a 
comparably poor symptom relief in both groups and poorer palliative care referrals among breast 
cancer than the gynaecologic cancer patients. Gynaecological cancer patients had higher 
symptom prevalence and higher symptom distress scores and lower performance status 
compared to the breast cancer patients. 
1 
Chapter 1 
INTRODUCTION 
The majority of patients with breast and gynaecologic cancers in developing countries present 
with advanced disease (1)(2). The required specialists and facilities to manage these patients are 
either non-existent or not affordable if present, in countries such as Nigeria (3)(4). This implies 
that a large number of our patients will require palliative rather than curative treatments on first 
presentation. While it is important to improve prevention, early detection and treatment of cancer 
to be able to achieve a cure, it is also vital to provide palliative care to those who cannot be cured 
(5). The focus of palliative care research and development has mainly been on the prevalence 
and relief of pain. Cancer patients are known to have numerous other problems apart from pain 
(6). The generalist clinics and wards that characterize many hospitals in Africa are unlikely to 
meet the needs of cancer patients. Cancer patients here are seen alongside other patients with 
benign conditions and as such, the special attention and sensitivity that is required for their care 
may not be available. Even though it may not be feasible to change this arrangement now or in 
the near future, insights into the symptom experiences of women living with cancer will help to 
guide and improve services.  
Clinical palliative care is essentially symptom oriented and symptom focused in its drive to 
improve the quality of life of patients facing life threatening conditions (7). Palliative care is 
relatively new in Nigeria and there is a need for clinicians to be familiar with the symptom 
pattern of cancer patients that are commonly encountered in this environment. Even though a 
palliative care team exists in the University of Ilorin Teaching Hospital, this team only sees 
patients that are referred to them and referral is at the discretion of the managing physician. 
Many patients with palliative care needs if not recognized by the attending physician and 
referred appropriately, will not be seen by the palliative care team. This study explores the 
symptom burden in women with breast and gynaecological cancers anticipating that the findings 
will better inform the managing doctors, the palliative care team and the hospital management on 
the needs and problems of these patients. This will serve as a guide for planning quality care that 
would help improve the quality of life of these patients. 
2 
SYMPTOM AS AN OUTCOME MEASURE 
The word ’symptom’ is derived from the Greek word-symptoma- and it is translated as ‘anything 
that has befallen one’ (8). The dictionary defines symptom as ‘’the subjective evidence of 
disease or physical disturbance observed by a patient’’ (9). The subjective nature of symptoms 
makes it an individualized entity even though the presence of a disease or its management or 
some other physical disturbances is central to its occurrence (10).  
The presence of symptoms is a major reason for health care utilization by a large number of 
patients (11). Symptom management has gained much importance now than before because 
patients and other stakeholders are now more inclined to treatments or interventions that address 
symptoms (12). Symptoms have become equally important endpoints or outcome measure to 
consider when choosing between treatment options for cancer to the extent that it is now at par 
with other important outcome measures such as survival time, tumour size or time to recurrence 
which before now, were previously the only important outcome measures that are usually 
considered in patients undergoing cancer treatments (10). 
Symptom burden portrays the cumulative effects of symptoms with their impact as it is observed 
or perceived by patients (12). A more comprehensive definition of symptom burden put forward 
by Gapstur (13) is ‘’the subjective, quantifiable prevalence, frequency and severity of symptoms 
that place a physical burden on patients and may produce negative physical, psychological and 
emotional responses’’. The expression ‘symptom burden’ is said to be invented by physicians 
who also view and approach symptom burden differently (14). It is sometimes used 
synonymously with symptom distress (15). Symptom burden report is dependent on the 
perspective of whom it is viewed. Many have assessed symptom burden from patients’ 
perspectives while others have done so from the health care providers’ views or from the family 
carers’ perspectives. Technically, symptom burden has been assessed through different 
modalities. Some have assessed it by simply noting the number of symptoms experienced by the 
patients (16)  while others have assessed it by determining severity of the symptoms, allotting 
scores to the severity ratings and then adding up such scores to arrive at symptom burden 
assessment (17,18). Some others have incorporated functional interference in their assessment of 
symptom burden (10). 
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The importance of symptoms and the burden they constitute is continually been investigated by 
several authorities. Refinement in its definitions, the scope of its effects on patients and their 
families as well as the health care providers and the need to continually improve on its evaluation 
and subsequent symptom management will continue to be an open area of research. 
SYMPTOM BURDEN IN CANCER PATIENTS 
Symptom burden in cancer patients is significant and symptoms are commonly present whether 
the cancer is amenable to curative treatment or the management focus will be palliative (19). 
While curative treatment is the focus of treatment in many illnesses, palliative care continues to 
be the main treatment modality in many chronic conditions including cancer (7). This is 
particularly so in developing countries where majority of cancer patients present at advanced 
stage of their disease (7). Cancer patients in developing countries are in a very precarious 
situation because they have a complex disease that often require multidisciplinary approach, 
requiring expertise that are often lacking in resource poor countries (3). Many cancer patients 
also usually traverse curative phase, palliative phase and subsequently, the end-of-life phase in 
the course of their illness. The transition through the phases may sometimes be dramatic and 
often unpredictable (20). Each of these phases of care is loaded with symptoms which often 
constitute significant burden to the patients with significant impact on patient well-being and 
quality of life. However, symptoms are often not explored and may often times go unnoticed by 
the health care providers (21). The magnitude of this symptom burden may be worse in 
developing countries where cancer treatment is most often suboptimal compared to developed 
countries (3). This unequal access to care is worse among the females in the developing countries 
compared to their counterparts in developed countries (22). 
Breast and cervical cancers together are the major cancer resulting in death in women in the 
developing countries (23), both constituting a third and a quarter of all new cancer cases and 
cancer deaths respectively in women (24). In advanced stages, both of these cancers are 
characterized by symptoms whose profiles are poorly documented in Nigeria. This study has 
highlighted the symptom profiles of women with breast and gynaecological cancers and 
comparisons were made between the groups with respect to symptom experiences. The study 
was carried out in a tertiary health care centre which is a prototype of a typical highest level of 
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care such women can access in Nigeria. The symptom experiences were documented using a 
validated symptom assessment tool.   
GLOBAL CANCER BURDEN 
The burden of cancer is commonly expressed as incidence, prevalence and mortality rates (25). 
The morbidity that accompanies cancer is usually not reflected in these statistics (26). However, 
more complex measures such as ‘’disability-adjusted life years lost’’ and ‘’persons-years of life 
lost’’ are the other estimates that attempt to describe the reduced quality of life and burden of 
disease experienced by the individual between diagnosis and death and also the impact of the 
disease on the society (25,27). 
The World Health Organization (WHO) estimates in 2002 reported that 10.9 million new cases 
of cancer occurred worldwide while 24.6 million people were living with cancer and 6.7 million 
people died of cancer (28). It was projected then that the number of new cancer cases would 
increase from 10.9 million in 2002 to 16 million in 2020, with the number of deaths also 
increasing from 6.7 million in 2002 to 10.3 million in 2020 (28). Recent global cancer report is 
in line with these projections. In the year 2012, 14.1 million new cases of cancer and 8.2 million 
cancer deaths were recorded (24). The growing cancer incidence and deaths are occurring 
majorly in less developed countries as was predicted. There has been a generally rising trends in 
the number of cancer cases occurring in the developing countries (28). In 1970, only 15% of new 
cases of cancer were from the developing countries and this rose to 56% by 2008 (29). Recent 
global cancer estimates reported that 57% of new cases are from less developed countries and 
also, 65% of all cancer deaths were also from the less developed countries (24). The implications 
of all these are that more patients with cancers are to be expected to confront the health care 
services in the developing countries, further overstretching the limited resources. 
CANCER IN DEVELOPING COUNTRIES 
Evidence of increasing proportion of cancers to occur in the developing countries abound 
(23,24,30,31). The reasons for these increases include aging population due to improved standard 
of living and increase in the adoption of cancer-associated lifestyles such as cigarette smoking 
and consumption of westernized diets (28,30). Improvement in the control of communicable 
diseases has also contributed to the apparent increase in cancer incidence (32). The truth 
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however is that most of developing countries are still battling with the double burden of disease - 
both communicable diseases like malaria and tuberculosis and the growing incidence of non-
communicable diseases like cardiovascular diseases and cancer (33,34). 
Sub-Saharan Africa is not prepared to face this growing disease burden (3). Comprehensive 
cancer care is still very difficult to be provided in many African countries because of poor health 
care systems that lack both the basic infrastructural facilities and the human resources (3,35,36). 
Health care policies are also not stable due to repeated disruption and fragmentations which 
sometimes result from political instability and conflicts (3,35). Even when higher numbers of 
cancer cases were reported for the developed countries, mortality rates for cancer were still 
disproportionately higher in the developing countries than the developed ones (23,28). Now that 
more cancer cases are to be expected from the developing countries, the resulting mortalities 
from cancers are likely to approach alarming proportions.  
Cancer survival rates are also much lower in the developing countries compared to the developed 
countries (37). For example, the 5-year survival rate for breast cancer in some African countries 
is less than 50% while it is more than 75% in developed countries (23,37). The reasons for the 
lower survival are multiple. Lack of appropriate treatment due to lack of expertise and/or 
equipment, poverty and lack of appropriate cancer drugs are very common in the developing 
countries (28,36). Another important contributor to poor cancer survival in resource poor 
countries is the limited funding allotted to these areas (35,37,38). The shift in cancer burden to 
less developed countries has resulted in 80% of disability-adjusted life years been lost to cancer 
in these areas, yet only 5% of the world’s resources to treat cancer are available here (35,37). 
These issues illustrate the task ahead for the developing countries if cancer survival is to be 
improved. 
 
CANCER SYMPTOM BURDEN IN DEVELOPING COUNTRIES 
Cancer patients are known to experience significant symptom burden resulting from the disease, 
its management, and other non cancer morbidities or a combination of all these (39). Treatment 
related symptoms usually occur while on treatment but it may sometimes persist even after 
treatment had been discontinued or the cancer itself had been cured (12)(40). These varying 
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sources of symptoms require regular assessment and re-evaluation as well as comprehensive 
discussion about the symptoms with the patients (41). Continuing advances in treatment options 
for many cancers and discoveries of newer therapies all imply increases in cancer survivorship or 
disease free intervals, which may in turn signify the development of more treatment related 
symptoms (41).  Many cancer patients in resource poor countries usually do not have access to 
either the conventional cancer treatments or the new emerging ones (42). The consequent of this 
is that the natural progression of the disease with its attendant symptom burden takes its natural 
toll on many of the patients. All the factors such as poverty, illiteracy and poor access to health 
care services that contribute to late presentation and eventual poor outcomes of the disease are 
particularly worse in women residing in resource poor countries (42-44). These women are 
culturally, educationally and socially disadvantaged compared to their female counterparts in the 
developed countries (22).  
Breast and cervical cancers are the two most common female cancers in the developing countries 
(23,24). Breast cancer together with all the gynaecological cancers accounted for about 1.6 
million out of the total of 3.8 million new cases of cancer in women in the year 2012 (24), 
constituting slightly over 40% of cancer cases that occurred in women. Over a quarter (28.3%) of 
all deaths from cancer in women were also attributable to breast and gynaecological cancers 
(24). Breast, uterine corpus and ovarian cancers were among the top ten new cancer cases in 
2012 in both developed and the developing countries, with uterine cervix cancer been additional 
in the developing countries top ten cancer cases (24). The predicted increases in cancer incidence 
and deaths for the developing countries are becoming evident in the recent cancer statistic 
reports.  
The rising trends in cancer cases in the developing countries are likely to soon overstretch the 
already meager health care systems which neither has the personnel nor facilities to handle them 
(45). Cancer screening services such as that of cervical cancer screening is an effective 
preventive measure that has helped in the drastic reduction of cervical cancer mortality in the 
developed countries (46). Such cancer screening services have been very difficult to establish in 
many developing countries like Nigeria because of the resources required for such services (46). 
But even if this and other preventive measures are established now, it is still unlikely that 
significant effects can be produced with respect to reduction in the number of cancer cases to be 
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expected for the next 10 years (28). Also, some cancers by virtue of their nature and location, 
coupled with some inherent patient factors, are not amenable to all preventive measures and 
continue to present in advanced stages for which cure is not possible and the patient will have to 
be palliated with symptomatic treatments only. With the present state of health care systems in 
many developing countries, symptom control by way of palliative care may be the only treatment 
available for many cancer patients in a long time to come. 
 
 
CANCER TREATMENT IN DEVELOPING COUNTRIES 
In order to achieve a good treatment outcome in cancer care, a multitude of skilled specialists is 
required to make prompt and correct diagnosis which is the followed by  appropriate treatments 
including but not limited to surgery, radiotherapy, chemotherapy and supportive care (38). These 
are scarce commodities in the many developing countries. In Cameroun, there were only 2 
oncologists to the 18.8 million populations as at 2010 (3). Similarly in Malawi, there was no 
trained oncologist in the whole country as at 2010 (47) . According to WHO, Africa has less than 
5% of the world’s specialized health care workforce to tackle cancer (3,35). The necessary 
equipment to diagnose cancer such as CT scan, mammography and colonoscopy are also very 
limited (47). Radiotherapy capacity in Sub-Saharan Africa is grossly inadequate and unevenly 
distributed (48,49). Sixty percent of all the radiotherapy machines in Africa are found in Egypt 
and South Africa (48).  Twenty-eight out of the 54 African countries lack radiotherapy facilities 
(49). In Nigeria as at 2008, there were 5 radiotherapy machines said to be available in the 
country (2). Considering the over 150 million population then, this is insufficient to serve the 
country. The recommended 0.4 radiotherapy machine per million of population is not likely to be 
met by many African countries (50). This gross shortage of radiotherapy facility is reflected in 
the long waiting list at the few radiotherapy centers available in Nigeria (2,48,49). The further 
implication of this for majority of the patients is the continuing disease progression resulting in 
worsening symptoms and symptom burden. 
Cancer treatment and prevention have not been given as much attention as it should have 
because it is misconstrued to be a disease of the affluent while communicable diseases had more 
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attention in the developing countries (51). International finances to resource poor countries have 
been directed mostly on HIV/AIDS, malaria and tuberculosis (52) even though reports have 
shown that cancer kills more people than all these diseases combined (28). Evidence of 
relegation of cancer to the background is further reflected in the just concluded Millennium 
Development Goals where cancer care/control was not a prominent feature (53). The present 
Sustainable Development Goals may end up in similar fate for cancer care if no proactive steps 
are taken because all the competing diseases are still very much present. Lack of priority given to 
cancer care and control is contributory to poorly informed patients who present with advanced 
diseases. 
Many cancer patients present very late in Africa. The knowledge about cancer is generally poor 
among the populace in the developing countries (54) and this implies poor preventive behaviors 
too (54). Limited resources contribute to poor availability of infrastructures, manpower, 
consumables, follow-ups and surveillance necessary for running many cancer screening 
programs (46). The few available services have been slow or fail to expand in many African 
countries (55). In Nigeria, cancer screening services are still poorly developed and the available 
services are underutilized (56-59). The lack of functional screening services contributes to 
advanced stages of disease that many patients present with. In a Nigerian study (43) on breast 
cancer patients, 75% of the patients presented with stage 3 or higher while in a similar study in 
Cameroun (44), 100% of the patients presented with similarly advanced stage of the disease. 
Both studies revealed that about half of the patients waited for more than six months with their 
illness before presenting to the hospital. 
Several reasons are purported for the late presentation in these countries. These include belief in 
sorcery and witchcraft as the cause of the illness, poverty that make health care unaffordable, 
lack of early recognition and referral by the initial doctors and stigmatization sometimes 
associated with the disease (43). Seeking alternative treatments before resorting to orthodox 
medicine also contribute to delay in presentation with consequent advanced stage of the disease. 
The poor health care systems in many developing countries also contribute to the advancement 
of disease and eventual poor outcomes (4)(60). Early presenting cancers can still end up with 
poor prognosis because of poor accessibility or unavailability of health care services when 
needed. All these factors result in a vicious cycle of disease progression with consequent 
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increased cost of treatment which further impoverish the patients, increasing toxicity from 
treatment, greater disease and symptom burden, resulting in poorer treatment outcomes, shorter 
disease free intervals, lower survival rate and overall worsening of patients’ quality of life (38).                          
 
BREAST CANCER OVERVIEW 
Breast cancer is the most common cancer in women worldwide, accounting for 25% of all 
cancers in women and 15% of cancer deaths (24). In Nigeria, breast cancer is also the 
commonest cancer in women (61), having overtaken cervical cancer (43,62). Despite higher 
incidences of breast cancer in the developed world, mortality is much lower than that in the 
developing countries, including Nigeria (62,63). Late presentation is a major problem in many 
breast cancer patients in developing countries and this has repeatedly featured in studies 
emanating from this part of the world (1,43,62,64). These studies have also shown that breast 
cancer in Black Africans tends to occur in premenopausal women compared to post-menopausal 
women in Caucasians. Also, the breast cancer in Africans is said to be more aggressive in 
behavior and are usually hormone receptor negative compared to the breast cancer types found in 
the Caucasians (64,65). Treatment for breast cancer, as with any other cancers in developing 
countries is suboptimal because of limited capacity for cancer care and poor awareness among 
the populace (4,45). A study (66) on the acceptance and adherence to treatments among breast 
cancer patients in Nigeria revealed that over a third of the patients declined any form of 
treatment and there was poor adherence to treatments with those on chemotherapy.  These 
factors together with poor health care systems in developing countries imply significant residual 
disease with considerable symptom burden in these women. 
Studies on symptom burden in breast cancer patients in this environment are very scarce. There 
are many studies (67-71) on the symptom burden in breast cancer patients in the developed 
countries but they are mainly on post treatment patients or those on treatments. Many patients in 
the developing countries are not on treatment because of illiteracy and poverty or unavailability 
of facilities and some others are sub optimally treated (4,47,66,72). The symptom profiles in the 
developed countries are likely to differ from those of the developing countries based on this 
difference alone.  
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Studies of breast cancer in Nigeria have been mainly retrospective. Many of the studies have 
looked at epidemiology of breast cancer with focus on prevention and possibly early detection to 
improve cure. Young age, premenopausal/peri-menopausal states of many women, relationship 
of the disease to parity, pregnancy and lactation and late presentations have been severally 
reported in many studies from Nigeria (1,64). Studies also abound on the histologic types of 
breast cancer in Nigeria with reports of the aggressive form being prevalent (64,65,73). Others 
have studied treatment challenges such as non-acceptance or non-adherence to treatment (66). 
Studies on the symptom profiles that characterize these women are poorly researched into. A few 
studies have mentioned the breast masses with fungating ulceration (74) and others have mention 
sites of metastasis and ensuing complications, but the symptom burden that accompany these 
pathologic states are rarely emphasized (1).   
 
 
GYNAECOLOGICAL CANCER OVERVIEW 
Gynaecological cancers encompass a diverse group of tumours with different epidemiological 
features, clinical presentation and treatment strategies (27). Cancer of the cervix, body of the 
uterus, vagina, fallopian tubes, vulva and gestational trophoblastic tumours are all types of 
gynaecological malignancies (75). Cervical, uterine corpus and ovarian cancers are the most 
common gynaecological cancers worldwide (24). According to the 2012 global cancer estimates, 
there were 735,200 new cases of gynaecological cancers (cervical, uterine corpus and ovary) in 
the developing countries, constituting 19.2% of all cancers in women (24). This is double the 
incidence of cases in developed countries where only 9.5% of all cancers in women were of 
gynaecological origin (24). 
Cervical cancer is the most common gynaecological cancer in the developing countries unlike 
developed countries where cancer of the uterine corpus is the commonest (24). It is the third 
leading cause of cancer deaths in women following breast and respiratory tract cancers (24). 
Uterine corpus cancer is next to cervical cancer in incidence in the developing countries and is 
closely followed by ovarian cancer (24). However, with regards to mortality, ovarian cancer is 
next to cervical cancer as leading cause of gynaecological cancer deaths worldwide as well as in 
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the developing countries (24). The other gynaecological cancers are relatively uncommon and do 
not feature in the leading causes of cancer incidences or cancer mortalities.   
Studies on gynaecological cancers in Nigeria have being more of epidemiologic with reports 
mainly on the cancer types and presentations with respect to age, parity, advanced stages of 
diseases and treatment challenges (2,76-82). Cervical cancer has been reported to be the 
commonest gynaecological cancer in almost all studies in Nigeria. Some other studies have 
reported on the histologic types of the cancers (80). Like breast cancer, majority of 
gynaecological cancer patients in the developing countries report for diagnostic and treatment 
services at advanced stage of their disease. Most studies have reported on poor treatment 
outcomes as well as challenges with treatment in view of the very scarce radiotherapy facilities 
and prohibitive cost of effective chemotherapy (50). Surgical interventions are also of poor 
outcomes because of advanced stages of diseases and lack of expertise (83). A few studies (77) 
have reported on the clinical presentations of the gynaecological cancer patients. Ijaiya et al in 
their review reported on the symptoms documented in the patients’ case notes (73). These 
include irregular vaginal bleeding, foul smelling vaginal discharge, weight loss, abdominal pain, 
urinary frequency, backache and hematochezia. Umezulike (84) also reported on similar 
symptoms in their study. No prospective study examining symptom burden in gynaecological 
cancer in Nigeria is available.  
PALLIATIVE CARE AND CANCER CARE   
Palliative care has been defined by WHO as an approach that improves the life of patients and 
their families, facing problems associated with life-threatening illnesses, through the prevention 
and relieve of suffering, the early identification and impeccable assessment and treatment of pain 
and other problems, physical, psychological, social and spiritual (85). Palliative care aims to 
reduce and possibly avoid the distress associated with terminal illnesses and helps to improve the 
quality of life of patients and their families (86). In many instances, cancer is a chronic illness 
which an afflicted person has to live with for sometime before death (86). The symptom burden 
during this period is usually enormous and most often challenging (86). 
Cancer patients in resource poor countries often present in advanced stages of their disease for 
which palliative care is the care plan right from presentation (7,47). Even though cure is the 
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appropriate aim of medicine, Callahan et al has rightly acknowledged that other goals of 
medicine are equally important such as promoting health, preventing illnesses and injury and 
relieving suffering and caring for those who cannot be cured (5). Cancer and its incurability in 
some cases is a long known fact, yet palliative medicine which is most suited provision for it 
only developed a few years ago (87). Medical training of health care professionals is almost 
exclusively curative and at best preventive in focus and orientation (88). This cure-oriented 
model of training has produced physicians that lack palliative care and end-of-life care skills 
(89), yet significant numbers of cancer patients in resource poor countries require and can only  
get this type of care.  
Palliative cancer care originated from developed countries and its effectiveness has been 
severally documented from those countries (89,90). Palliative care has attained much advanced 
stages of development in developed countries where integration into the health systems is 
common as well as recognition of palliative medicine as a specialty or subspecialty in medicine 
(89,90). These advances in palliative care in the developed countries are continuing despite the 
fact that cancer incidences are on the decrease, survival are better and treatment advances in 
cancer care is ever advancing  in these countries.  Developing countries on the other hand with 
the increasing cancer incidence, unavailability of cancer treatments and poor outcomes for 
cancer patients is yet to have palliative care readily available (90). This unavailability of 
palliative care is in spite of the relatively low cost and low technology required in the provision 
of palliative care (91). A few countries in Africa have actually made significant progress in 
palliative care development and integration into existing health care systems, but a larger 
majority of the African countries including Nigeria have not done so (92).    
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Chapter 2 
LITERATURE REVIEW 
This literature review was compiled by searching databases through Ebsco, Pubmed and Google 
Scholar platforms from University of Cape Town’ health sciences library website. Chapters in 
books were also manually searched and Google Scholar searches. The words that were used for 
the searches include: cancer statistics, breast cancers, gynaecological cancers, cancer treatments, 
developing countries, Africa, symptom burden, symptom assessment, palliative care, and 
symptom assessment tools/instruments, developing countries, Nigeria, Africa and Sub-Saharan 
Africa. These words and phrases were variously combined in the search strategy. 
 
SYMPTOM PREVALENCE IN CANCER PATIENTS 
Symptom prevalence studies have been conducted in various patient populations with cancer 
diagnosis. Yamagishi et al (93) studied symptom prevalence among cancer patients undergoing 
active anticancer therapy. The study consisted of patients with diverse cancer diagnosis but all 
commencing chemotherapy newly. Some other studies have been done on homogenous cancer 
populations, for example, Tasmuth  et al (69) examined a cohort of early breast cancer patients 
that were exposed to surgical intervention. Barbare et al (18) on the other hand examined an 
extremely diverse patient population, consisting of patients with different cancer diagnoses, 
varied stages of disease, different treatment plans including curative, palliative as well as 
unclassified. Their large sample of over 45,000 patients also included patients with other non 
cancer morbidities as well as patients in different locations of treatments such as home care or 
hospital outpatients. Barbare et al’s study is a population-based study that can only be conducted 
in countries with accurate medical recording systems including cancer registry. While such 
elaborate study may be difficult to replicate in developing countries where medical records 
including cancer registry are poorly kept, the large number of participants in this study makes it a 
valid study to refer to. These studies have all shown the ubiquitous dimensions of cancer patient 
populations that have been studied with the implication of extremely divergent outcomes that 
would be inherent to each and every study, given the varied patient populations, and varied 
stages of the diseases and treatments as well as different settings of studies. However, despite 
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these various cancer populations studied, comparative studies on symptom prevalence between 
different cancer types are not commonly available. 
The symptoms reported in various symptom prevalence studies in cancer patients are quite 
different as would be expected from the cancer types apart from other differences like treatments 
or stages of the disease. A systematic review of the symptom prevalence and impact of multiple 
symptoms in cancer patients was carried out by Kim et al (94). The review reported on 18 studies 
involving a range of 26-527 patients. Fatigue, worrying, feeling nervous, dry mouth, insomnia, 
feeling sad/moody, feeling irritable, pain, drowsiness and distress in decreasing frequency were 
the 10 most prevalent symptoms reported.  Fatigue was the most prevalent, occurring in 62% of 
the patients. An earlier but larger study by Saskia (95) on a similar group of patients reported 5 
symptoms- fatigue, pain, weakness, lack of energy and lack of appetite as the most prevalent. 
Here again, fatigue was the most prevalent but together with pain were the only symptoms that 
were similar to both studies, showing differing symptoms reported. Kim et al examined only 
those studies that made use of 3 specific validated instruments while, the study by Sakia 
incorporated studies that extracted symptoms from questionnaires developed by the researchers 
and studies that used medical record documentations in addition to numerous other studies that 
used validated instruments . This probably resulted in the varying numbers of symptoms and the 
types of symptoms reported. In contrast to these two studies, Barbera et al (18) in their large 
statewide study in Ontario Canada, examined symptom prevalence in cancer patients using a 
single instrument to assess symptoms in over 45,000 patients. Report from this study was based 
on a 9-item symptom assessment instrument. Fatigue was still the most prevalent followed by 
poor well-being, poor appetite and being anxious. Again, fatigue is noted to be a common factor, 
but the other symptoms are different from those of the earlier studies.   
It has been well acknowledged that cancer symptoms may result from the disease itself, the 
treatments side effects or complications from the treatments as well as from other possibly co-
existing medical conditions (39). Symptom prevalence in cancer patients are likely to be 
influenced by these entities. Tasmuth et al (69) studied pain and other symptoms in 93 patients 
that had radical or conservative surgery for non-metastatic breast cancer. Even though some 
patients underwent other forms of treatment apart from the surgery, the main symptoms studied 
were exclusively in relation to the surgical intervention. The authors examine specifically 
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symptoms such as pain, oedema, numbness, weakness of arm phantom sensations in the removed 
breast and ipsilateral arm. This study overlooked other symptoms that may have arisen from 
chemotherapy, radiotherapy or a combination of these that some of the participants actually had. 
A similar study on patients receiving chemotherapy only, irrespective of initial cancer therapy 
was also conducted by Yamagishi et al (93). A total of 462 patients commencing chemotherapy 
newly were examined with questions that were relatively but not exclusively specific to 
chemotherapy-induced symptoms. The authors came up with 4 symptom clusters with the most 
frequently mentioned symptoms being oral problems, insomnia, psychological distress, severe 
fatigue, and severe appetite loss. The identified symptoms were more commonly associated with 
chemotherapy. These studies show that symptom prevalence study reporting on post treatment 
symptom experiences may vary greatly, depending on the treatments received by the study 
participants and the focus of the researcher.    
 
SYMPTOM PREVALENCE STUDIES IN BREAST CANCER 
Symptom prevalence studies in breast cancer patients like for any other cancers are also similarly 
done on patients that are either on anti-cancer treatment or in the post treatment period. Breast 
cancer treatments are basically surgery, chemotherapy, radiotherapy or hormonal therapy. Some 
patients undergo all these treatment modalities while some others have a selected combination of 
these. The majority of studies on symptom prevalence in breast cancer patients are from the 
developed countries where treatments are promptly administered unlike the developing countries 
where treatments are not readily available. While it cannot be assumed that treatment related 
symptoms in these studies are all attributable to the treatments received entirely, disease-related 
symptoms cannot always be discretely enucleated from patients’ reports on symptoms in many 
of these studies.         
A study on treatment-related symptoms in low-income women with breast cancer in Califonia 
was conducted by Maly et al (70).  All the women in the study were enrolled in a treatment 
program. They examined only 3 symptoms –depression, nausea and pain-in the study population 
of 921 women. These 3 symptoms were chosen because earlier studies in their environment had 
highlighted these to be the most prevalent symptoms in breast cancer patients undergoing 
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chemotherapy or radiotherapy. Depression was the most prevalent symptom but least recognized 
by the physicians, while pain and nausea were less common but better recognized by the treating 
physicians in that study. Even though low-income women in this study may be likened to women 
in the developing countries like Nigeria, only 3 symptoms examined in these women is too few 
to be compared in women from developing countries where disease burden of breast cancer is 
more. Sucala et al (96) investigating the role of multidimensional symptom and dysfunctional 
beliefs as predictors of quality of life in breast cancer patients on chemotherapy reported more 
elaborated symptom profiles. They reported on 145 breast cancer patients. An average of eleven 
symptoms was noted with a range of 0-26 symptoms. The most prevalent symptoms reported 
were dry mouth, lack of energy, numbness, difficulty sleeping, sweats, and body image issues, 
feeling sad and worrying. Gwede et al (97) conducted a similar study with respect to stage of 
disease and treatment status, and also using a similar assessment tool albeit slightly modified to 
that of Sucala et al. They explored symptom experiences in homogenous breast cancer patients 
and came up with 2 different patient subgroups- the low-symptom burden group and the high-
symptom burden group. They reported on chills, emotional upset, change in taste, pain, muscle 
weakness, change in appetite, diarrhea, nausea, problem with urination and dizziness as the most 
prevalent symptoms in the high-symptom burden subgroup of patients identified in that study. 
These last two studies have examined patients with early stage breast cancer populations. Studies 
on a mixture of early and late breast cancer patients as well as on mixture of patients on 
treatment and those not on treatments that characterize many hospitals in developing countries 
are not commonly available. Knowledge of the symptom prevalence in these various mix of 
cancer patients is equally important especially for the generalist physicians who are the bulk of 
doctors that attend cancer patients in developing countries like Nigeria.     
Tasmuth et al (69) studied 93 breast cancer women who had radical or conservative surgery for 
breast cancer. The authors examined symptoms one day prior to surgery and then at 3 other times 
postoperatively. While the symptoms assessed prior to surgery could have been very informative 
as far as pre-treatment symptom status was concerned, the authors seemed to have examined 
symptoms that were almost specifically associated with the surgical intervention that was 
planned. The study revealed more physical symptoms post operatively than pre-operatively. The 
symptoms reported on were restricted to pain, disturbed sleep, numbness, arm oedema, phantom 
sensation and muscle weakness which were all noted to be increased post operatively than pre-
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operative. Anxiety and depression were however reported to be decreased post operatively than 
the prevalence noted before surgery. Chen et al (71) also looking at pre-surgical symptom 
profiles in early breast cancer patients as a predictor of quality of life 2 years later examined 
somewhat different but just 5 symptoms in a group of 198 Taiwanese women. The 5 symptoms 
which were extensively assessed using a structured questionnaire for each symptom were 
attentional fatigue, physical fatigue, sleep disturbance, depression and anxiety. These two studies 
examining similar patients with respect to stage of disease as well as surgical intervention have 
examined and produced divergence symptom profiles. Tasmuth et al(69) have examined 
symptoms from the view of effects expected from surgery while Chen et al have done so from 
the perspective of effects on quality of life. The possible symptoms that can be examined even in 
homogenous cancer patients are quite numerous. When other differences such as different 
disease stages or treatments given are considered, the list of symptoms would be even more 
incomprehensible for routine clinical use.      
In an attempt to provide a collection of symptoms that would cut across breast cancer patients in 
different phases of the disease, Bender et al (98) did a composite study on breast cancer patients 
across the 3 phases of disease.  The first phase consisted of patients who just had surgery for 
early stage breast cancer and had not commenced chemotherapy, the second phase study 
consisted of patients that have had both surgery and chemotherapy and some were on hormonal 
therapy while the third phase patients had metastatic disease. Symptom profiles for each of these 
phases were highlighted and symptom clusters for each phase were identified. A-thirteen item 
symptoms list used for the study was extracted from four different tools but some of the 
symptoms selected were still similar in meaning or closely related. For example, fatigue, feeling 
of lack of energy and decreased physical strength/weakness were listed as separate entities. The 
symptoms that cut across all the 3 phases in the study were fatigue, feeling depressed, feeling 
anxious, feeling of lack of energy, loss of concentration and weakness. Symptom prevalence in 
metastatic breast cancer was reviewed by Irvin et al (99) in an overview of symptom 
management in patients with metastatic breast cancer. Fatigue, depression, insomnia and pain 
were most prevalent symptoms in addition to metastasis site specific symptoms. The patient 
population in the third phase of Bender et al study (98) was those with metastatic breast cancer. 
The symptoms that were reported in this group of patients were feeling lack of energy, fatigue, 
feeling anxious, feeling depressed, difficulty sleeping and loss of concentration. Comparing the 
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symptoms in these two similar cancer groups, only fatigue, depression and insomnia were 
similarly reported by both authors.    
Depression is a very common symptom among breast cancer patients in the literature. Maass et 
al (100) did a systematic review on the prevalence of depression and anxiety among breast 
cancer patients who were at least one year post diagnosis. They reviewed 17 studies and reported 
depression prevalence of 9.4 to 66.1%. They concluded that depression was commoner in breast 
cancer patients compared to the general population and that it persisted though of decreasing 
intensity over 5 years after diagnosis. This study however examined only those studies that 
recruited breast cancer patients treated with curative intents. They excluded those with advanced 
disease whose prevalence and trend of depression and anxiety may be different. Stafford et al 
(101) in Australia examined women with breast and gynaecologic cancer for depression at 
diagnosis and then followed them up for a year. Patients with anxiety, depression or both were 
more prevalent at diagnosis and the rate significantly reduced at 8 weeks and 24 weeks post 
diagnosis. The two patient groups were found to be significantly different with respect to marital 
status, location of residence and treatments received for their cancer. The stages of cancer which 
has important influence on symptoms were however not mentioned in that study and it would 
therefore be difficult to compare their findings with that of Tasmuth and Maas. The study 
however agreed with others that depression and anxiety improved over time in the study 
populations.       
Each of these studies had reported on the different symptoms that were commonly observed in 
the different patient populations studied. Divergent as the symptom reports have been, they have 
helped to shed more light on the symptom profile possibilities that would guide in planning 
appropriate care and support to the diverse problems identified in patients studied. 
 
 
SYMPTOM PREVALENCE IN GYNAECOLOGIC CANCERS 
Symptom prevalence studies in gynaecological cancers have been commonly done in the 
different individual cancers that are of gynaecologic origin.  Many of the studies have been on 
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the most common cancers such as ovarian, cervical and uterine cancers. Patients on active 
treatment either primarily (102) or in clinical trial settings (103) were more commonly studied. 
Others were patients in the post treatment period or cancer survivors (100). Patients referred for 
palliative care interventions are another commonly observed group of patients for which 
symptom prevalence studies have been carried out.  
Generally however, gynaecological cancers have some symptoms that may be common to them, 
while some other symptoms are peculiar with the specific cancer type. In a review of 
gynaecological cancers by Mishra (75), vaginal bleeding was reported to be the most common 
presenting symptom in cervical, endometrial and vaginal cancers, but less common with ovarian 
cancers. Others symptoms common to gynaecological cancers are vaginal discharge, 
constipation, diarrhea, nausea, vomiting and pain (75).  Some pathologic states arising from 
genital cancers include symptomatic anaemia, obstructive uropathy, deep vein thrombosis, 
lymphedema, bowel obstruction, rectovaginal and vesicovaginal fistulae and a host of 
psychological issues (75)(84). All of these pathological states present with their unique 
symptoms. 
Klee et al (104) in a study on cervical cancer patients’ perspectives on physical symptoms after 
radiotherapy followed 118 patients for up to two years. There were significant drop out of 
patients over time in that study but symptoms that were noted in the first 3 months after 
radiotherapy were diarrhea, nausea, and lack of appetite, frequency of micturition, dysuria, 
vaginal discharge, tiredness and weakness. The baseline symptoms prior to the commencement 
of therapy that would have made pre- and post-treatment symptoms better compared were not 
documented. Instead, a control group was used for comparison.  All the symptoms listed were 
noted to be higher in the patients than the control group in the study. A baseline symptom profile 
could have provided symptom that could be attributable to the disease before onset of 
radiotherapy.    Karin Ahlberg et al (102) in Sweden in a similar study but on patients treated 
with radiotherapy for uterine cancer, examined fatigue and a limited number of other symptoms. 
Their study aimed to explore the experience and relationship of fatigue and these other 
symptoms and also in relation to global quality of life for 60 patients referred for curative 
radiotherapy after surgery for uterine cancer. The symptoms selected were based on symptoms 
identified from other studies as being commonly associated with radiotherapy. Risk of 
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overlooking certain symptoms is present in this study especially if an assessment tool had not 
been used in identifying the key symptoms. The study examined fatigue, pain, diarrhea, loss of 
appetite, nausea/vomiting and insomnia at baseline and then at 3 weeks after commencement of 
radiotherapy and at the end of the treatment. They reported increase in all the symptom severity 
from baseline compared to subsequent measurements even though not all symptom differences 
reached statistical significance. Both of these studies have examined different cancer types 
exposed to radiotherapy. Symptom profiles in patients requiring radiotherapy and not getting it 
or receiving other forms of treatments instead of radiotherapy is also important especially for 
clinicians that practice in resource limited countries.   
Symptom prevalence studies in ovarian cancer patients are commonly found in patients with 
advanced disease some of which may be undergoing clinical trials with chemotherapy. Jensen et 
al (105) studied 51 patients with stage 3 or 4 ovarian cancer with a newly developed 18-item 
symptom assessment tool. They came up with a number of symptoms and concerns reported by 
the patients.  Fatigue, difficulty sleeping, constipation, nausea and pain were the top symptoms 
noted. Other concerns mentioned by the study participants were inability to enjoy life, varied 
contentment with quality of life, inability live an independent life, feeling ill and worrying that 
condition will get worse. Friedlander et al (106) in a multicenter study involving 18 centers 
across Australia and Canada examined symptom burden and outcome of treatment in patients 
with platinum resistant/ recurrent ovarian cancer. Patients were given palliative chemotherapy 
planned for a certain number of cycles, but more than half of the participant did not complete the 
cycles for reasons such death and adverse effects. The baseline symptoms that were commonly 
nominated by the patients were pain, fatigue, abdominal bloating, nausea, vomiting, bowel 
dysfunction, anorexia, hot flushes, dyspnoea and urinary problems. Emotional distress and 
insomnia were also mentioned. Donovan et al (103) did a systematic review to determine the 
recommended patient-reported core set of symptoms and quality of life domains to be used to 
measure in ovarian cancer treatment trials. The reviewed studies were from United States, 
Canada, Europe and Hong Kong. They identified abdominal pain, bloating, cramping, fear of 
recurrence/disease progression, indigestion, sexual dysfunction, vomiting, weight gain and 
weight loss as the core symptoms specific to ovarian cancer. Symptoms in ovarian cancer 
patients in developed countries are likely to be similar to that of the developing countries 
because ovarian cancers generally present in advanced stages anywhere (27) (105). However, 
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differences may be discovered between developing and developed countries with respect to 
adequacy of debulking surgeries and newer chemotherapeutic agents that may not be available to 
patients in the developing countries. These are important differences that may impact on 
symptom burden and may need to be explored in other to plan appropriate palliative/supportive 
care for ovarian cancer patients in developing countries like Nigeria.                      
A number of studies have also been done in gynaecological cancer patients referred for palliative 
care interventions. Kim et al (107) in their review of symptoms among advanced cervical cancer 
patients referred for palliative intervention reported pain, constipation and emotional distress as 
the most prevalent symptoms while anorexia, poor well-being, fatigue and insomnia were 
clinically significant symptoms as well.  Aeckele et al (108) in their review of 225 breast and 
gynaecological cancer patients admitted to a Palliative care unit of a University hospital in 
Germany reported weakness/vertigo, pain, anorexia, nausea and vomiting as the most common 
symptoms. Although the study was not a comparative one, the most prevalent symptoms among 
cancer groups were highlighted. Breast and ovarian cancer patients were most bothered by 
weakness/vertigo while cervical cancer patients had pain as the most prevalent symptom. 
Elumelu et al in a similar retrospective study (109) in palliative care patients in Ibadan, Nigeria 
also reported on breast and cervical cancer patients enrolled in the outpatient Palliative care 
services of a tertiary health care centre. Also not a comparative study, pain, vomiting, nausea and 
weight losses were the most common symptoms in both groups of women. Other symptoms 
similarly found in both patient groups were fatigue and lymphoedema. Chest symptoms (cough 
and dyspnoea) were exclusively found in breast cancer patients while gynaecological cancer 
patients exclusively had anorexia. Elumelu et al in the Ibadan study compared cervical cancer 
only with breast cancer patients. Even though cervical cancer is the commonest gynaecologic 
cancer in Nigeria as in other developing countries, uterine and ovarian cancers are also fairly 
common and ovarian cancer is particularly known for significant morbidity and mortality among 
the gynaecological cancers (27).            
SYMPTOM ASSESSMENT 
Symptom assessment is a continuous process that is imperative right from the diagnosis of a 
disease condition and continues during monitoring of therapeutic interventions or disease 
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progression (110). The assessment of symptoms is a prerequisite for adequate and appropriate 
planning of quality care; yet comprehensive symptom assessment is not commonly performed in 
everyday clinical practice (17).   Symptom assessment is important in cancer care because cancer 
patients frequently suffer from severe and multiple symptoms for which they seek symptom 
control with or without interventions for the underlying cancer. Symptom assessment like any 
other patients’ needs assessment involves information gathering with the aim of identifying 
clinical needs that can be met (111). This information seeking requires a trusting relationship 
between the health care provider and the patient in order to be able to have an open and honest 
communication (120).  Sophie et al(113) in a focused group discussion among health care 
professionals involved in cancer care at a University hospital in Sweden reported that striking up 
a relationship between the patient and the doctor is an important factor that influence symptom 
management. This relationship they further emphasized would only be created when 
doctors/nurses are readily available to attend to patients unhurriedly, individualize patients’ care, 
instill confidence in patients as to the care to expect and encourage patients’ participation in the 
care plan. 
Clinical assessment of symptoms is confronted by a lot of challenges which constitutes barriers 
to good symptom control (114,115). Pain is the most studied symptom in clinical practice as well 
as in research settings. Problems and barriers to pain assessment and management have been 
severally studied and some successes have been reported (116). Even though pain management is 
not yet optimal (116), many lessons learnt from pain management so far can be extrapolated to 
other non-pain symptoms in cancer care. 
 
PAIN AS A PROTOTYPE UNDERTREATED SYMPTOM IN CANCER PATIENTS 
Pain is one of the most feared and most burdensome symptoms in cancer patients (117). Pain is 
also one of the most prevalent symptoms in cancer populations. The prevalence of pain in cancer 
patients range from 30-60% in early stages of cancer and may rise to over 60% in patients with 
advanced cancer (118). Van den Beuken et al (117)in a systematic review on the prevalence of 
cancer pain in a varied cancer population reported a pooled prevalence of >50%, with the highest 
prevalence noted in head and neck cancer patients. Annelio Vamio (119) in a similar study on 
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symptom prevalence in patients with advanced cancer also reported prevalence of moderate to 
severe pain as 51%, ranging from 43% in stomach cancer to 80% in gynaecological cancers. 
Others have similarly reported pain as the most prevalent symptom (6) (120)or among the top 
five most prevalent (18) (95)(121) symptoms in their studies . It has been proposed that control 
of cancer pain should be feasible in up to 90% of cases (21) but this has not been the case. 
Despite research and guidelines on pain management, pain remains undertreated in both 
developed and developing countries (122,123) . Pain in cancer is not physiologically different 
from those arising from other conditions, but the psychosocial and existential dimension to 
cancer pain makes it unique (112). Pain is also very important in that the presence of pain 
frequently influences the occurrence of some otherwise stand-alone symptoms such as sleeping 
disorders and depression (124). 
In examining pain under treatment in Italy, Zenz (123) conducted a 3-year survey of the 
prescription pattern among German physicians. The study accessed 330 practices across 
Germany through computerized medical records of their prescriptions. The study revealed that 
only 1.9% of cancer patients were prescribed strong opioids and many of the prescriptions 
authorized inadequate dosing intervals. The study concluded that majority of cancer patients in 
Germany were not treated for pain at all and that those treated are grossly under treated. Andrea 
(21)in a systematic review of under treatment of pain examined 26 studies involving cancer 
patients. Pain Management Index (PMI) was used in assessing pain under treatment in this study. 
PMI relates the severity of pain report by patient to the level of analgesia prescribed by the 
physician. The authors acknowledged that PMI is a rough guide since other factors such as 
pathologic cause of pain, use of adjuvant or non-pharmacologic pain therapies or patients’ 
compliant with treatment also influence adequacy of pain control. The study however concluded 
that nearly one of two patients (43%) with pain was undertreated. Apolone (125) in a multicentre 
study on the quality of cancer pain management in Italy reported lower overall prevalence of 
pain under treatment of 25% even though some of the centers had up to 55% prevalence. There 
seem to be a decreasing trend in the reported prevalence of cancer pain under treatment. A 
follow up study on that of Andrea was carried out by Greco et al (116). They systematically 
reviewed studies from 1994 to 2013, including that of Andrea; and further specifically reported 
on the prevalence of under treatment from 2007 to 2013. Twenty studies were reviewed from 
2007 to 2013 and the mean prevalence of under treated cancer pain was 31.5% compared to 
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41.5% for the year 2001-2008. They reported a decrease in the prevalence of cancer pain under 
treatment to the tune of 25% at an approximately 1% decrease per year. Factors that were found 
to be predictive of pain under treatment were having a good performance status, early disease, 
minority groups or less educated individuals and when there is discrepancies between the 
patients’ and the physicians’ rating of severity of pain (21). Greco (116) also reported being 
managed in nonspecific settings as predictors of pain under treatment and this was similar to 
Apolone’s(125) finding that patients in the palliative /hospice centers had better pain treatment 
than those in an oncology setting. It was unanimously agreed by many authors that under 
treatment of pain reported in many of the studies were attributed to inadequate pain assessment. 
These inadequacies were attributed to barriers that have been variously classified.  
The barriers to symptom assessment have been classified as physician-based, patient-based and 
health care system-based (114,126). Malathi et al in their study to identify barriers to symptom 
management in a sample of 768 cancer patients in India classified these barriers as 
communication, personal, professional, financial and misconception barriers (127). Health-care 
providers contribute to inadequate symptom assessment in a number of ways. These include their 
training, their knowledge and their attitude (128). The cure-oriented background of physicians’ 
training portrays diseases as having clear-cut pathophysiology with straight forward treatments 
(88). Symptoms whose pathophysiologies are uncertain constitute an uncomfortable zone for 
many physicians (88). The implication of this training is that unclear symptoms are not assessed 
and even when noticed, are not treated or are undertreated (21). 
Poor knowledge is also a common reason for not assessing and treating pain among health care 
professionals. Devi et al (128) examined the barriers to cancer pain management among 253 
doctors working in government hospitals in Sarawak, Malaysia. The study revealed that half of 
the doctors would not prescribe morphine for fear of respiratory depression, while over a third of 
them because of fear of addiction. The study concluded that knowledge about pain management 
was poor among the respondents and restriction on morphine was high. Liao et al in a similar 
study in China (129) examined assessment of cancer pain management among new fellows. 
Many of the fellows were of different disciplines like medicine, surgery, anaesthesia, ENT and 
paediatrics. The fellows reported that their training in cancer pain management was poor and this 
they linked majorly to poor pain assessment skills. Result from the survey revealed that barely 
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half (49%) of the physicians correctly responded to clinical scenarios on management of cancer 
pain. 
Attitude and behavior of health workers are also recognized barriers to symptom assessment. The 
assumptions that patients would volunteer symptoms without being asked leave many symptoms 
unaddressed (126). Bias of treating similar cases differently can be attributable to individual 
doctor’s attitude (130)  and this can significantly impact on patients’ symptom management. 
Patient-based barriers to pain assessment are also enormous. The assumption by the patient that 
the doctor should know that symptoms are present in them is quiet common (126). Others 
include fear of addiction to opioids, worrying about side effects of drugs, financial constraints to 
buy prescribed drugs and misconception about drugs for pain (126,127). Fear of disapproval by 
doctor or family carer and not to be seen as ungrateful also constitutes a common barrier to 
symptom reporting (126). Studies have also reported that patients may not report symptoms for 
fear of being disqualified from clinical trials (131). 
Institutional barriers to pain management were elaborated by Kwon et al in their review (115). 
Inadequate availability of medications especially opioids and poor interventional pain services 
due to lack of expertise and equipment was highlighted in the review. Lack of support services 
from specialists in pain and palliative care and psychosocial supports services were also 
identified as important barriers to pain management. Anorlu (2) in her review of cervical cancer 
in sub-Saharan Africa noted that poor co-ordination across multiple care providers is also a 
commonly reported challenge in cancer care because many of specialists needed in cancer care in 
Africa for instance, work in isolation. In many health institutions, poor staffing with high patient 
load per doctor or nurse, lack of privacy due to overcrowded wards and clinics gives little time 
for adequate patient evaluation for symptom assessment (126). 
SYMPTOM ASSESSMENT BY PATIENT, CARER OR HEALTH CARE PROVIDER 
Symptom assessment is central to symptom management in cancer care (132). The subjective 
nature of symptom means there are multiple ways of assessment as well as method of checking 
symptom reports with more objective means (133). However, patients’ self-report of their 
symptom experiences are still considered the most appropriate means of assessing symptoms and 
are superior to proxy assessments (110).  Nekolaichul et al (132) in a prospective study of 49 
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patients with advanced cancer compared symptom assessment by a proxy such as a doctor or 
nurse and that of the patients themselves. The study reported that both doctors and nurses more 
often underrated patients’ symptoms but the underrating was worse by doctors than the nurses. 
Oechsle et al (134) in a similar study incorporated family member in the comparison. Their own 
study reported that physicians underrated symptoms while family members on the other hand 
overrated the patients’ symptom severity. Nekolaichuk and Silveira et al (132,135) studied these 
proxy assessments over time in order to discover a trend but noted no improvements. Oechsle et 
al (134) further examined dimensions of frequency, intensity and distress to each symptom as a 
pointer to treatment indication. They discovered that treatment indication was based on symptom 
intensity and not frequency. Inaccurate symptom assessment by proxy therefore could have 
significant implications leading to overtreatment or inadequate treatment of symptoms. 
Many symptom assessment tools are designed for patients to respond (135) while some others 
are constructed for the carer to respond (136). Proxy symptom assessments are sometimes 
necessary because cancer patients, especially in the advanced stages may be too ill to engage in 
conversations or may be cognitively impaired by their disease to engage in any meaningful 
communication (132). 
Symptoms harvested from symptom assessment are dependent on several factors. These factors 
include patients’ factors, disease factors, the informant’s factor as well as the method or tool that 
is used to obtain such information. Un-captured symptoms will continue to infringe on the 
patients’ comfort and reduce quality of life. While little can be done to patients’ and disease 
factors, a lot could be done to improve the methods of collection of this vital information in order 
to improve on care and support to be provided. 
 
SYMPTOM ASSESSMENT TOOLS 
A symptom diary which captures the daily fluctuations of symptoms and has potential to reduce 
recall bias is said to be the gold standard for symptom record but, this method of symptom 
assessment is not acceptable for many patients because of the burden it imposes on them and the 
high rate of non compliance by the patients (110).   Symptom assessment tools in the form of 
questionnaires are better alternatives to diary recordings (110). The tools are structured 
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documents containing the list of symptoms to be assessed and how they should be assessed. 
Availability of these tools should help to improve symptom assessment and subsequent 
management but this is yet to be generally acceptable to all health care providers.  
The use of symptom assessment tools in eliciting symptoms in patients is evidenced based but 
unlike other evidence based clinical practices, it is yet to be widely accepted by health care 
providers (137). Many healthcare professionals have not adopted the use of symptom assessment 
instruments despite the evidences from research that have shown that structured interviews are 
more accurate in eliciting symptoms(138) and lead to better symptom control as well as better 
improvement in the quality of life of patients(139). Reasons that have been reported for poor 
compliance with the use of these tools by the health care providers include concern over the 
clinical practicability, burden of such measurements especially in busy clinics and 
uncertainties/unacceptibility of its usefulness or importance (137).  Others have reported poor 
clarity on its use and the processes involved; some see it as an abnormal way of eliciting 
symptoms from patients while difficulty in the interpretation of the scoring systems/scales was 
also seen as an issue by others (140). 
Bainbridge et al (141) surveyed the perception of 128 health care professionals on the use of a 
symptom assessment tool (ESAS) in a regional cancer centre in Ontario, Canada. The survey 
revealed that nearly half of the physicians do not agree that ESAS would enhance patients’ care 
and a noticeable number expressed that the tool was of no benefit to them in usage. Pereira et al 
(142) in a larger but similar study on same issue surveyed 960 health care providers in 14 
regional cancer centers also in Ontario. Their report was that of significant discrepancy between 
the health care workers’ attitudes to the use of symptom assessment tool and the reported actual 
use of the tool (ESAS).  They also reported that about one third of the respondents do not refer to 
the tool while 44% believe in taking their own history from patients for assessing symptoms.  
Until more efforts are directed at combating these concerns, the acceptance of the symptom 
assessment tools by the healthcare professionals may remain poor.  
Symptom variability occurs in response to treatments or as disease progresses (143). These 
symptom changes may have implication for the tools to be used if comprehensive symptom 
assessment is to be achieved (143). While the use of one symptom assessment over time allows 
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trends in symptoms changes to be glaring, this may not be appropriate all the time (144). 
Lasheen et al (144) in a study on symptom variability in hospice patients reported apparently 
static symptom prevalence over 5 consecutive days. The median number of symptoms at 
admission and 5 days afterwards was 4, but the quality of the constituent symptoms differed. The 
number of participants in the study also decreased over the time of study with 125 enrolled and 
30 completing the study in the 5 days.  A similar study by Spichiger et al, examining symptom 
changes over a 10 day period in similarly hospitalized cancer patients reported an average of 13 
symptoms at admission and 9.3 symptoms 10 days later (145). Also, number of participants 
decreased from 103 to 53. The patients in both studies were comparable but the number of 
symptoms reported differed greatly. The symptom assessment tool used in eliciting symptom 
prevalence is a key determining factor of the symptoms to be elicited. The earlier study by 
Lasheen et al assessed only 6 symptoms albeit through 2 different methods while the later used 
MSAS which consisted of 32 symptoms. Variability of symptoms could also be viewed from the 
perspective of the actual symptom changes apart from number. The development of new 
symptoms and disappearance of others as was demonstrated in both studies constitute symptom 
variability that may have implication for the symptom assessment method or tool to be used to 
capture these changes. The single assessment tool used throughout the course of symptom 
monitoring in both studies may also explain some drop out of patients who became too sick to 
continue with the study for which a different method or tool may have been more appropriate to 
use.   
To further demonstrate the changes in symptom quantity and quality with the commencement of 
treatments and the effect of the assessing tool, Spichiger et al (146) studied symptom changes 
over 3 months in cancer patients commencing chemotherapy with the aid of MSAS. The study 
reported high symptom prevalence prior to treatment and further hike in the number of 
symptoms with commencement of treatments, but symptom scores for each individual symptom 
greatly varied both within and between individual patients over time. Yamagishi et al (93) in 
similar study looked at the dimension of symptom distress using Distress Thermometer and then 
symptom number, by using MDASI. They reported decrease in distress caused by the symptoms 
over time and increase in physical symptoms only in those with increased symptom distress. 
Both of these studies have shown difficulty in comparing outcomes even in similar patient 
populations being assessed for similar parameter. This difference may probably be because of the 
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different assessment tools employed in the studies. The need to individualize symptom 
assessment with respect to patients’ needs as they arises and the need to identify the appropriate 
tool to use to capture these changes as they arise is important in symptom prevalence studies. A 
symptom assessment tool that has an adequate amount of the symptoms that are commonly 
observed in cancer patients would be better at capturing symptom changes.   
The Memorial Symptom Assessment Scale (MSAS) 
The original MSAS consisting of 33 symptoms was developed by Portenoy et al and the 
reliability and validity of the tool was evaluated in cancer patients in 1994 (147). It is a symptom 
assessment tool with multidimensional measurement of each symptom. Further revision of the 
original tool resulted in the present 32 symptoms now present consisting of 28 physical 
symptoms and 4 psychological symptoms. The tool has an allowance of 2 optional symptoms to 
be added if present. Twenty-four symptoms are assessed by their frequencies, severities and the 
degree of distress they cause using 4 or 5 Likert scales. The remaining 8 symptoms for which 
frequency of occurrence seem inappropriate such as weight loss and hair loss were assessed with 
respect to severity and how much they caused distress. All symptoms were assessed based recall 
period of the preceding one week. The 28 physical symptoms are assessed for degree of distress 
or bother they constitute. The frequency of occurrence and the severity of the symptoms are 
omitted. The 4 psychological symptoms are assessed for the frequency of occurrence only.   The 
shortened form ensures that patients’ burden in completing the form is reduced and also the time 
to completion is shorter (148).         
The MSAS-SF has been shown to be equally valid and like the revised MSAS, further subscales 
can be obtained from it (148). The Global Distress Index (MSAS-GDI) is a 10 item composite 
consisting of 4 psychological symptoms (feeling sad, feeling irritable, worrying and feeling 
nervous) and 6 physical symptoms (lack of energy, lack of appetite, pain, feeling drowsy, 
constipation and dry mouth) it measures the overall symptom distress. The MSAS-GDI has been 
found to be clinically relevant as it correlates predictably with quality of life and patients’ 
clinical status (147).The physical symptom subscales (MSAS-PHYS) is obtained from the 
average score of 12 prevalent physical symptoms. These are lack of appetite, lack of energy, 
pain, feeling drowsy, constipation, dry mouth, nausea, vomiting, change in taste, weight loss, 
feeling bloated and dizziness. The scaling of the degree of distress for each symptom is in 0.8, 
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with 0 being no symptom, 0.8 for symptom present but causing no distress, up to maximum of 4 
for symptom causing very much distress. 
The psychological symptom subscale (MSAS-PSYCH) is obtained from the average scores of 6 
prevalent psychological symptoms. These are worrying, feeling sad, feeling nervous, difficulty 
sleeping, feeling irritable and difficulty concentrating. The scoring for the psychological 
symptoms is in increments of 1, with 0 being no symptom at all and 4 for the symptom that is 
almost constantly present. The total MSAS score is the average score of all the 32 symptoms 
present in the MSAS-SF.  
MSAS-SF was chosen for this study because of its broader number of symptoms, its ease of 
completion and the several subscales that can be derived from it. Although it has not been 
validated in African settings, it also being used in African studies (6) (149). It has been translated 
into several African languages in the studies that used it among cancer population (6). 
Edmonton Symptom Assessment Scale (ESAS) 
The original ESAS was constructed by Bruera et al in 1991(150). It was construed to be used 
frequently in palliative care setting and could be completed by the patient themselves or with the 
help of a nurse or relative (150). It consisted of 8 symptoms initially but it was later increased to 
9 with further allowance of one additional optional symptom to be added if present (151). The 
original tool was a visual analogue scale of 10-100mm but further modification was done to 
create the 11-point numerical scale from 0-10 (152). Synonyms for some of the symptoms were 
also introduced, for example, tiredness/fatigue. This was done to increase its acceptability and 
usability by patients (153). The 9 symptoms contained in ESAS are pain, tired, nausea, 
depression, anxiety, drowsiness, appetite, well-being and shortness of breath (154).   
Most of the studies that used ESAS in symptom assessment were done in Canada, United States 
of America and other similarly developed countries (152). None seem to have been done in 
African settings (155). The visual analogue format and the numerical rating scale style of this 
tool also makes it not appropriate for African setting where many patients are illiterates and may 
find it difficult to comprehend (41). A categorical grading of symptom will be more appropriate 
in this environment. The very few number of symptoms assessed also made it inappropriate for 
use here. These were the reasons why the tool was not selected for this study. 
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MD Anderson Symptom Inventory (MDASI). 
MDASI consists of 13 symptoms that are rated on an 11-point scale from 0-10, with 0 meaning 
‘’not present’’ and 10 indicating ‘’as bad as you can imagine’’ (17). It also has 6 interference 
items to indicate how the presence of the symptoms interferes with other aspects of normal living 
(17). These interference items are also rated from 0-10, with 0 meaning ‘’did not interfere’’ and 
10 meaning ‘’interfere completely’’ (156). The 13 core symptoms are: fatigue, disturbed sleep, 
distress, shortness of breath, drowsiness, dry mouth, sadness, difficulty remembering, numbness 
or tingling, lack of appetite, nausea and vomiting (156). The interference items are in relation to 
others, enjoyment of life, mood, walking, general activity and working (156) . The combination 
of symptom severity and the interference are used to measure symptom burden.  
The primary MDASI was designed for 24 hour recall of symptoms, but other time periods such 
as the previous one week is said to be available on request (156). The tool is very easy to use and 
can be completed in 2-5 minutes (126). There are also various means of administering MDASI. 
It is available in pencil and paper format, interactive voice response system, tablet PC and also 
web-based applications (156). 
MDASI was not chosen for the study because it requires an undisclosed amount of money to be 
paid to the authors before it can be used (156). It also involves protocols and permission before it 
can be translated it can be translated to local languages (156). MDASI has also not been used in 
an African setting (157) unlike MSAS. 
 
Karnofsky Performance Scale (KPS) 
Performance status is an estimate of a patient’s level of functioning with regards to carrying out 
daily activities and self-care (158) (159). It assesses the level of independence a patient possesses 
and determines how much activities such individual can perform by themselves (158). 
Performance statuses have been shown to correlate with symptoms and certain symptoms are 
associated with poor performance status (160,161). The performance status is also useful in 
much clinical decision making including recruitment for clinical trials (162). It is an important 
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determinant of treatment commencement, continuation, interruption as well as termination and 
these in turn impact on survival and quality of life (162).   
There are various instruments that are also available for measuring performance status, but the 
two commonly used are the Karnofsky Performance Scale (KPS) and the Eastern Cooperative 
Oncology Group (ECOG)(163).  A new instrument called the Functionality Assessment 
Flowchart (FAF) has recently been developed also for assessing performance status in cancer 
patients (162). It is a modification of both KPS and ECOG and said to have higher inter-observer 
agreements than the previous two (162). KPS was chosen for this study however because of its 
long standing use in clinical practice. It is a clinician-rated performance scale and consists of 11-
point rating scale from normal functioning scored as 100 through to 0 score for dead.  
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RATIONALE FOR THE STUDY 
Many cancer patients have to cope with this significant symptom burden. Pain and other 
symptoms experiences by cancer patients in Africa are poorly researched (164) and the 
unaddressed symptoms continue to contribute to poor patients’ and their families’ satisfaction 
with health care services. Data on symptom prevalence other than pain are scarce in many 
developing countries. Most of the available studies are on symptom prevalence in cancer patients 
from the developed countries and these cannot be assumed to be similar to ours because of 
differences demographics, culture and health care systems (6).  Breast and gynaecological cancer 
are the major killers of women in Nigeria (165,166). Hospital based mortality records in Lagos, 
Nigeria reported breast cancer as the most common cause of death (165). A similar review on 
mortality from the gynaecological unit of a similar tertiary health care centre in Nigeria reported 
that 88% of deaths from the gynaecological unit were from cancer cases and the remaining 12% 
were from benign conditions (166). The prevalence and burden of symptoms in these major 
women killer diseases are insufficiently documented. In Nigeria, most of the studies in the 
women have been mainly retrospective with focus on clinical presentations (77,167), 
identification of risk factors (64), treatment outcomes (62,66) and challenges of management 
(66)(83)  . No study has examined the symptom prevalence prospectively nor has any study been 
done on the groups of women using a validated symptom assessment tool. The aim of this study 
was to explore and compare the symptom experiences among breast and gynaecological cancer 
patients in a tertiary health care institution with the view to identify their symptom burden and 
make comparison that will inform future management decisions and lead to overall improvement 
in the care given to help improve on the quality of life of the patients.   
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AIMS AND OBJECTIVES 
AIM: 
 To explore and compare the prevalence of the different symptoms among breast cancer and 
gynaecological cancer patients accessing care in University of Ilorin Teaching hospital (UITH). 
OBJECTIVES: 
1. To determine the prevalence of symptoms among breast cancer and gynaecological 
cancer patients accessing care in UITH, Ilorin. 
2. To determine the most distressing symptoms experienced by breast and gynaecological 
cancer patients accessing care in UITH, Ilorin.  
3. To assess symptom relief in the two studied groups. 
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Chapter 3 
METHODOLOGY 
STUDY DESIGN 
The study was a comparative descriptive cross-sectional hospital-based survey. 
STUDY SITE 
The study was conducted at the surgical outpatient and gynaecology outpatient clinics and the 
corresponding inpatient wards of the University of Ilorin Teaching Hospital, Ilorin, Kwara State 
of Nigeria. 
STUDY POPULATION 
The study population was all eligible breast cancer and gynaecology cancer patients admitted 
into the female surgical ward and gynaecology ward and also similar patients attending the 
respective outpatient clinics. The study was conducted from 20th October 2015 to 15th of April, 
2016.  
 
SELECTION CRITERIA 
The following were the inclusion criteria for the selection of participants: 
1. Confirmed  breast cancer or gynaecology cancer 
2. Patient over 18 years of age 
 
The following were the exclusion criteria for the selection of participants: 
1. Patients who were in extreme distress such that communication was not possible. 
2. Patients who were unable to give consent, for example, an unconscious patient.  
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SAMPLE SIZE 
The sample size calculation was based on the equation developed by Robert Lehr (168) to 
estimate sample size for two study groups.  
(n): n = (16SD2)/D2 
Where n is the estimated sample size per group,  
SD is the projected standard deviation of the mean (in this case 7 from previous study (6)),  
and D is the desired, or clinically important, difference between the two groups (D=4).  
Assumes that α (or the P value) is 0.05, that β is 0.20 (power of 80%), 
n= 16(72)/42 
=49 
Sample size of at least 49 was used per group. 
 
STUDY SAMPLE 
There was no sampling done in the study but all eligible patients that were attending UITH for 
care as either outpatient or inpatients were enrolled. All eligible patients were enrolled as they 
presented to the hospital until the desired sample sizes were reached for both groups of patients.  
 
STUDY PERIOD 
Recruitment of patients for the study begun on the 20th October 2015 and the last patient was 
recruited on the 15th April, 2016. 
 
DATA COLLECTION  
Data Collection Tools 
The data collection tool consisted of three parts: 1) a participant data sheet; 2) the Memorial 
Symptom Assessment Scale Short Form (MSAS-SF); 3) the Karnofsky Performance Status. The 
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MSAS-SF was used during the initial interview with the patient and again at the second 
interview with the patient. 
1) The Participant data sheet  
This was used to record the socio-demographic details of the participant. Information for this 
sheet was obtained mainly from the patient’s case notes with occasional supplemental 
information from the patient. The socio-demographic details obtained included the age, religion, 
educational level, ethnicity, occupation and phone numbers. Other details obtained were the type 
of cancer, the duration of disease as recalled by the patient, the stage of the disease, and 
indication for present admission (for in-patients), both current and previous cancer specific and 
non cancer specific treatments received and involvement or non-involvement of hospital 
palliative care team in the management. The staging systems for breast and gynaecological 
cancer are different. The breast cancers were staged using the Tumour, Node and Metastasis 
(TNM) staging systems. The gynaecological cancers were staged by FIGO staging systems for 
the various gynaecological cancer types. Both the TNM and FIGO systems stage cancers from 
0/1 to 4. 
The participant data used for this study was a modification from a similar study in the literature 
(3).  
2) The Memorial Symptom Assessment Scale Short Form (MSAS-SF) 
This is a validated tool for symptom assessment and it was used to document symptoms that the 
patient had experienced in the preceding seven days prior to the interview. The original MSAS 
tool was developed by Portenoy et al in 1994 (147) and has been validated in cancer patients. 
The MSAS-SF is a modification of the original tool and it has also been validated among cancer 
patients in New Jersey in the year 2000 (148). It has not been fully validated in Africa or Nigeria, 
but a pilot study of MSAS-SF was conducted in Uganda (169). MSAS-SF has also been used in 
several African studies (6) (169). The MSAS-SF is a 32-item validated assessment tool 
containing 28 physical symptoms and 4 psychological symptoms. It has space for additional 
symptoms that may be present but not included in the list. Participants are required to answer yes 
to symptoms that are present and then go further to state how much the symptom bother or 
distress them for physical symptoms; and for psychological symptoms, patient are to state how 
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often the symptoms occurred. The distress levels of the physical symptoms are recorded on a five 
point Likert scale of 0.8 to 4 at an incremental rate of 0.8 i.e individuals whose symptoms did not 
bother them at all, those with a little bit of bother, those somewhat bothered, those bothered quite 
a bit and those very much bothered are scored, 0.8, 1.6, 2.4, 3.2, and 4.0 respectively. The 
frequencies of the psychological symptoms are also recorded on a four point Likert scale of 1 to 
4. Those whose symptoms rarely occur are scored 1, those with occasional symptoms are scored 
2, those with frequently occurring symptoms are scored 3 and those with almost constantly 
present symptoms are score 4. The MSAS sub-scales which are the physical subscales (MSAS-
PHYS), psychological subscales (MSAS-PYSCH), and the global distress Index (GDI) are 
obtained from selected symptoms from the MSAS. The detail of these symptoms and the scoring 
method is illustrated at the appendices.   
The MSAS-SF was translated into Yoruba, Igbo and Hausa languages. The translation into 
Yoruba and Igbo languages was done by Dr Adeyemi and his colleagues of the department of 
Language of the University of Ilorin while the Hausa translation was done by Mr Jibril of 
department of Hausa at the Ahmadu Bello University, Zaria. The translation was done into these 
languages and back to English language to check the accuracy of the translation. These are the 
three main languages in Nigeria.  The MSAS-SF and the participant’s data sheet were pretested 
on 4 patients at the nearby general hospital in the state. Three breast cancer and one gynaecology 
cancer patients were used for the pretest. The pretest showed the need to include telephone 
number in the study proforma and it further confirmed that the whole interview process takes 
between 10-15 minutes. The MSAS-SF was interviewer administered in order to cater for some 
patients that may be illiterate and also to keep the information as uniform as possible. 
3) The Karnofsky Performance Status was used to assess the functional status of the 
patients. It is an 11-point scale from 0% to 100% with 0% being dead and 100% being 
normal functional status. This assessment was done by observing the patient and also 
asking questions related to activities of daily living. This assessment was carried out by 
the researcher alongside the interviewing process. 
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Data collection process  
Introduction to the study site 
Having obtained ethical approval from the University of Cape Town, faculty of health Sciences, 
Human research Ethics Committee, the University of Ilorin teaching hospital ethical board and 
permission from the respective heads of departments, the researcher introduced the research to 
other key consultants and matrons in the clinics and wards. The clinics were such that 2 or 3 
different clinics were run at the same time with the patients all sitting in same area. The Surgical 
Outpatient clinic for instance had orthopaedics, cardiothoracic, paediatric surgery and urology 
clinics all alternating sharing of clinics with the general surgery clinics. The general surgery 
clinics are the places to identify breast cancer patients and breast cancer patients are just a 
proportion of their overall patient load. Since there are no breast oncologists, all the general 
surgeons attend to all breast cancer patients on all their different clinic days. The gynaecology 
clinics were less cumbersome but since there were also no gynaecology oncologists, all 
gynaecological cancer patients were being attended to by the gynaecologists in their different 
clinic days. The general surgery clinics were run by mornings while gynaecology clinics run in 
the afternoons. The wards were much calmer and serene and the matrons in charge were more 
constant and easily approached. They were informed about the study and their cooperation was 
given.  
Recruitment of participants 
Participants were recruited while they were waiting to be seen by their doctors at their respective 
clinics. In the clinics, the matrons in charge of the case notes were approached for case notes of 
general surgery patients or gynaecology patients respectively and assisted in identifying patients 
who met the selection criteria. Potential participants were approached individually and invited 
into a private room where they were informed about the study and invited to take part in the 
study. They were informed about the aims and conduct of the study and were told that their 
participation was voluntary and that if they choose not to take part in the study, they would not 
be penalized in any way.   They were assured of confidentiality and were told that their 
participation would not interfere with their being attended to by their original doctors. They were 
informed that they would be interviewed now and then again in a week or two either by another 
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physical encounter or via telephone. Those who agreed to participate were then given patient 
information sheet to read and take away. The content of the information sheet was explained to 
those who could not read using the language of their choice which were English, Yoruba, or 
Hausa. Those who chose to participate were asked to sign or thumb prints a consent form. 
 
 
Data Collection Method 
The participant’s data was first extracted from the case notes with occasional confirmation from 
the patients. A separate notebook was used to obtain the patients’ name, hospital number and the 
assigned study number only. Thereafter, the MSAS-SF was administered by the researcher in the 
language of their choice and the participants’ responses were documented. Each participant was 
asked for the presence or absence of the symptoms in the last one week and the degree to which 
they were bothered or distressed by each of the physical symptoms and the frequencies of the 
psychological symptoms.    
After completing the MSAS-SF, the researcher then rated the patient’s functional status by 
observation and also asking some activity related questions. The Karnofsky performance score 
was allotted as appropriate.  The participant was thanked for taking part in the research and was 
reminded that she would be seen or spoken to again.  
The fourth part of the assessment was the repeat of the MSAS-SF after an average of 7-12 days. 
This second contact with the patients was done by telephone contact because majority of the 
patients were seen at the outpatient clinics. Having noted the status on treatments, the second 
contact was to assess relief of symptoms or changes in the symptoms using the MSAS-SF as a 
check list with reference to the previously mentioned symptoms. A new MSAS-SF form was 
used for the second interview.  New symptoms were noted and recorded as for first time while 
the previously noted symptoms were noted for degree of relief described as totally relieved, 
significantly relieved, slightly relieved, same or worse.  No scoring was allotted to this grade of 
relief. Several calls were made before some could be spoken to again. This resulted in varied 
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interval of one week to 4 weeks between the first and second contacts. Some patients were lost to 
the study and not contactable even after several attempts at calling.  
 
Data storage and confidentiality 
The notebook containing the participants’ names and numbers and the consent forms were kept 
separately and away from participants’ data sheets and the two MSAS-SFs. Completed data 
sheets were kept in a locker by the researcher in her personal library. Data were entered into the 
researcher’s personal computer which is pass-worded. The note book containing the participants’ 
names and hospital numbers with the allotted study numbers was also kept in the researcher’s 
personal library and separate from the data sheets.      
 
 
DATA ANALYSIS  
Data collected on a designed proforma was sorted and manually checked for data clarity and 
errors before entry by the researcher. Data were entered into SPSS version 20.0 (Statistical 
Products and services Solution formerly called statistical package for social services [IBM-SPSS 
inc Chigaco, II, USA version 20.0]). Data exploration was also done to ensure accuracy. 
Tables and graph was used to report descriptive statistics. Categorical variables such as patients’ 
demographic information, stage of disease and symptoms documented among the two groups of 
patients was presented as proportions and frequencies. 
Categorical variables like patients’ demographics, stage of disease and symptom burden was 
compared using Pearson’s Chi-squared test or Fisher’s Exact test to test for significant 
association between these variables. Fisher’s exact test was used if the expected cell frequencies 
were below 5. 
For continuous variables, means, median and standard deviations and interquartile ranges (IQR) 
were computed. The continuous variables were observed for normality with the aid of histograms 
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or boxplots. Student’s t-test was used to test for significant association between the continuous 
variables with normal distribution while those with skewed distribution had the level of 
significant association tested for by the Mann-Whitney test. The following continuous variables: 
age, number of symptoms, duration of symptoms, MSAS-PHYS, MSAS-PSYCH, and TMSAS 
were compared between the groups. The level of significance was set at p<   0.05. 
 
 
ETHICAL CONSIDERATIONS 
The study obtained permission from the Human Research Ethics Committee of the University of 
Cape Town and the ethical committee of University of Ilorin Teaching hospital, Ilorin, Nigeria. 
The heads of departments of Surgery and Gynaecology were both approached after obtaining the 
ethical approvals. A letter of permission with the attached letter of approval from the ethical 
committee was submitted to each of the departments and their heads were also physical seen 
afterwards to further brief them on the study. They both passed the information to their other 
consultants in their various departments. The hospital palliative care team was also informed 
about the study and their support and co-operation sought. 
The study involved no direct intervention to the participants and so there were no obvious risks 
to the patients. However, patients with cancer are considered vulnerable by virtue of the nature 
of their disease. This study population therefore required additional protection. This was ensured 
by affirming the ability of the patients to communicate for a period of 10-15minutes from the 
ward nurses in the case of the inpatients and from the accompanying relatives for the outpatients. 
For patients that looked frail, the interview was maintained at a pace they could cope with. These 
patients may also be considered vulnerable because of the power imbalance in patient-doctor 
relationship which may put patients under pressure to accept to participate in research against 
their wish. This was eliminated from this study because the researcher introduced herself as a 
doctor who does not work in the hospital. The patients were also told that they were being seen 
by the permission of their primary physicians who is responsible for their care entirely. 
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The study was of some benefits to some of the patients. The study was an opportunity for some 
patients to know about palliative care. Occasional patients with palliative care needs when 
identified were discussed with the primary physicians. The physicians then refer the patients to 
the palliative care team.       
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Chapter 4 
RESULTS 
Sociodemographic information 
The study was conducted among 99 cancer patients. Fifty (50.5%) of them were breast cancer 
patients while 49(49.5%) were gynaecology cancer patients (Table 1). All were accessing care at 
the University of Ilorin teaching hospital as either outpatients or inpatients. Of all the patients 
approached for the study, one patient refused and gave no reason for her refusal. Table 1 shows 
summary of the socio-demographic information of the study population. The overall mean age of 
the study population was 55.23+ 13.12; median age was 56 years and the age range was 25 to 85 
years. About two-thirds (63%) were Muslims and the remaining were Christians. A little over a 
third (36.4%) of the patients had no formal education while about a quarter (26.3%) of them had 
tertiary level of education.    
Table 1: Socio-demographic information of the study population 
Factor  N (%) 
Age  
Mean + standard deviation 
Median 
Range 
 
55.23 + 13.12 
56.00 
25-85  
  
 
Educational level 
 None 
Primary 
Secondary 
Tertiary 
 
36 (36.4) 
20 (20.2) 
17 (17.2) 
26 (26.3) 
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Religion 
Islam 
Christianity 
 
63 (63.6) 
36 (36.4) 
Diagnosis                                                                                     
Breast cancer 
Gynaecologic cancer 
50(50.5) 
49 (49.5) 
 
Age Distribution by diagnosis 
Gynaecology cancer patients were older than the breast cancer patients with a peak age incidence 
of 60- 69 years while breast cancer patients had peak age incidence of 40-49 years, figure 1. The 
mean age for breast cancer patients was 52.76+ 13.51 while the mean age for gynaecology 
cancer patients was 59.78 + 11.85. The difference in the mean ages between the two groups was 
statistically significant (p= 0.008). However, there was no significant difference in the peak age 
group, p= 0.171 
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Figure 1: Age distribution and peak ages for breast and gynaecology cancer patients.  
 
   
 
 
 
 
 
 
 
 
 
P=0.171 
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Educational Status by diagnosis 
Table 2 shows the educational status of the participants. Breast cancer patients were more 
educated than the gynaecological cancer patients with half (50.0%) of them having at least a 
secondary school level of education while only about one third (36.7%) of the gynaecologic 
cancer patients had at least, a secondary school level of education. The differences in the 
educational levels between the two groups were not significantly different (p=0.331). 
 
Table 2 : Educational status of participants in the two groups 
Educational level Breast cancer Gynaecological 
cancer 
P-value 
None  17(34.0%) 19(38.8%) 0.331 
Primary  8(16.0%) 12(24.5%)  
Secondary  8(16.0%) 9(18.4%)  
Tertiary  17(34.0%) 9(18.4%)  
Total  50 49  
 
Stage of disease by diagnosis 
Table 3 shows the stages of the diseases at the time of interview in the two groups. At least 80% 
of both groups of patients were seen with at least stage 3 diseases. The stages of the disease were 
not statistically different between the two groups (p=0.241)  
 
Table 3: Distribution of stage of disease by diagnosis 
Stage of disease Breast cancer n (%) 
(TNM staging) 
Gynaecologic cancer n (%) 
(FIGO staging) 
P-value  
Stage1 2(4.0) 0(0.0) 0.241 
Stage 2 8(16.0) 4(8.2)  
Stage 3 29(58.0) 36(73.5)  
Stage 4 11(22.0) 9(18.4)  
Total  50 49  
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Table 4 shows the educational status by stage of disease of the participants. More of the patients 
with no education (92%) and those with primary level (100%) presented at advanced stage of 
their disease (stages 3 and 4) than the more educated patients with secondary school (58.8%) and 
tertiary level (84.6%) and this was statistically significant (p= 0.02).  However, the highest 
proportion (30.8%) of tertiary education level patients had stage 4 disease compared to all the 
other lower levels.   
 
Table 4: Educational level by stage of disease for all the participants 
Educational level Stage 1 Stage 2 Stage 3 Stage4 Total p- value 
None  0 3 27 6 36 0.02 
Primary  0 0 17 3 20  
Secondary  1 6 7 3 17  
Tertiary  1 3 14 8 26  
Total  2 12 65 20 99  
 
 
 
Location of patient 
Table 5 shows the location of patient for the interview. Majority of the gynaecological patients 
were seen as inpatients while most of the breast cancer patients were seen at the outpatient 
clinics. The difference in the inpatient/outpatient status between the two groups was statistically 
significant with more gynaecological patient being inpatients (p=0.000). 
Table 5 Location of patient at the time of interview 
Inpatient/outpatient Breast cancer n (%) Gynaecological cancer n 
(%) 
P-value  
Inpatient  5(10.0) 24(48.9) 0.000 
Outpatient 45(90.0) 25(51.9)  
Total  50 49  
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Involvement of palliative care team 
Table 6 shows involvement of palliative care team at the time of the interview. More 
gynaecological cancer patients were being seen by the palliative care team than the breast cancer 
patients, but the difference between the two groups was not statistically significant (p=0.121). 
 
Table 6: Involvement of palliative care team in patient management in the two groups 
Involvement of 
Palliative team 
Breast cancer n (%) Gynaecological cancer n (%) P-value 
Yes  3(6.0) 8(16.3) 0.121 
No  47(94.0) 41(83.7)  
Total  50 49  
 
 
 
Treatment Status 
Table 7 shows the status of treatment. Over 90% of gynaecological cancer patients were not on 
any treatment at the time of the interview while only one third of breast cancers were not on 
treatment. Of the 10 that had completed treatment among the breast cancer patients, 7 were still 
on hormonal treatment and follow up; two had completed hormonal therapy for 5 years and was 
just on follow up and 1 had exhausted all available cancer treatments options. Gynaecological 
cancer patients that had completed treatment also had exhausted all the available treatments 
options. Majority of breast cancer patients had ongoing cancer treatment which was mainly 
chemotherapy and/or hormonal therapy and a few were perioperative. Of the 15 breast cancer 
patients not on any anti-cancer treatment, 5 had financial constraints in procuring 
chemotherapeutic drugs, 6 were awaiting palliative surgery, 4 were admitted for correction of 
anaemia, and one was admitted due to respiratory distress. Of the 46 gynaecology cancer patients 
not on any anti-cancer treatment at the time of the interview, 9 were awaiting chemotherapy, 11 
were awaiting surgery, 11 were already referred for radiotherapy but yet to go and 15 were still 
being evaluated. The difference in the treatment status between the two groups of patient was 
statistically significant (p=0.000). 
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Table 7: Status of treatment at the time of interview in the two groups 
 
Status of current 
treatment 
Breast cancer n (%) Gynaecologic cancer n 
(%) 
P-value 
Ongoing 22(44.0) 0(0.0) 0.000 
Abandoned  1(2.0) 0(0.0)  
Completed  10(20.0) 3(6.1)  
Interrupted  2(4.0) 0(0)  
Not on treatment 15(30.0) 46(93.8)  
Total  50 49  
 
 
Duration of disease by diagnosis 
Table 8 shows the duration of disease as at the time of interview. The median duration of disease 
for breast cancer patients was 12 months (6-25) while it was 7 (5-16.5) months for gynaecology 
patients. The median duration of disease was statistically different between the two study 
populations (P=0.022). More gynaecology patients were within six months of their disease than 
breast cancer patients (48.9% versus 26%) but this difference was not statistically significant 
(p=0.071). 
 
Table 8: Duration of disease in the two groups of patients 
Duration of disease Breast cancer n (%) Gynaecologic cancer n (%) P-value  
Less than 6 months 13(26.0) 24(48.9) 0.071 
7-12 months 15(30.0) 13(26.5)  
13-24months 10(20.0) 7(14.3)  
25- 36 months 4(8.0) 0(0.0)  
More than 36 months 8(16.0) 5(10.2)  
Total  50 49  
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Table 9 shows the duration of symptoms by the educational levels of the participants. The mean 
duration of symptoms among the participants were not significantly different between the 
different education levels (p=0.318).  
 
Table 9: Mean Duration of disease by the educational levels of the participants  
Educational 
levels 
Number  Mean  Standard 
deviation  
95% confidence interval for 
mean 
Lower bound          Upper 
bound 
p-
value 
None  36 15.2 15.0 10.1                           20.3 0.318 
Primary  20 14.1 15.9 6.6                             21.5  
Secondary  17 22.5 26.8 8.7                             36.3  
Tertiary  26 22.7 25.3 12.5                           32.9   
Total  99 18.2 20.6 14.1                           22.3  
 
 
Comparison of number of symptoms, MSAS subscale scores and KPS between the study 
groups. 
Table 11 shows the average number of symptoms, the MSAS subscale scores and the Karnofsky 
Performance Scores in the two groups. The number of symptoms on the MSAS-SF (which 
consisted of 32 symptoms) range from 0-17 for all patients and when additional symptoms (extra 
1 - 3 symptoms) were considered, the number of symptoms ranged from 0-18.  
 
The overall number of symptoms for breast cancer patients ranged from 0-18 while it ranged 
from 0-17 for gynaecologic cancer patients. The mean number of symptoms for breast cancer 
patients was less than that of gynaecologic patient (5.48 + 4.21 versus 7.12 + 4.64, p=0.068). 
This difference did not reach statistical significance.   However, with additional symptoms 
(MSAS plus), the mean numbers of symptoms for Breast Cancer was significantly less than that 
of the symptoms for gynaecological cancer patients (5.82 ±4.50 versus 8.06±4.63, p=0.016).   
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Gynaecological cancer patients had higher scores for two of the MSAS subscales as shown in 
table 10. MSAS-PHYS (p=0.001) and GDI (p=0.040) subscales were significantly different 
between the two groups. The MSAS-PSYCH (p=0.216), TMSAS (p=0.054) and TMSAS with 
additional symptoms (p=0.234) were comparable between the two groups.  
 
Table 10: Average number of symptoms, the MSAS subscales scores and the Karnofsky 
Performance Scores in the two groups of patients 
Parameter (Mean±SD) Breast cancer Gynaecological 
cancer 
P-
value 
Number of symptoms on MSAS-SF 5.48 + 4.21 7.12 + 4.64 0.068 
Total number of symptoms with 
additional(MSAS-SF plus) 
5.8 + 4.5 8.1 + 4.6 0.016 
TMSAS (without additional symptoms) 
#TMSAS (with additional symptoms)                   
0.41 + 0.36 
0.88 + 0.72 
0.56 + 0.41 
0.70 + 0.39 
0.054 
0.234 
Karnofsky Performance Status 85.80 + 16.91  77.35 +  17.41 0.016 
Parameter (Median, IQR)    
GDI  0.48(0.06-0.98) 0.88 (0.28-1.27) 0.040 
MSAS-PHYS 0.26(0.00-0.63) 0.53(0.24-1.27) 0.001 
MSAS-PSYCH 0.40(0.00-1.06) 0.67(0.00-1.50) 0.211 
    
SD=standard deviation;   IQR=Interquartile range 
# TMSAS = computed only for the 50 patients with additional symptoms 
 
 
Karnofsky Performance Status 
The Karnofsky performance status (KPS) for this study population ranged from 40-100%.  The 
mean KPS for breast cancer patients was significantly higher, 85.80 + 16.91 compared to 77.35 + 
17.41 score for gynaecological cancer patients (p=0.016). More breast cancer patients, 20 
(40.0%) had almost normal scores compared to gynaecologic cancer patients 6 (12.2%) (Table 
11). 
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Table 11 Karnofsky Performance Statuses of patients in the two groups 
Karnofsky Score (0-100) Breast cancer n 
(%) 
Gynaecologic cancer n 
(%) 
p-
value  
Disabled (40) 2(4.0) 1(2.0) 0.007 
Requires considerable assistance (50) 3(6.0) 7(14.3)  
Requires occasional assistance (60) 0(0.0) 6(12.2)  
Cares for self (70) 6(12.0) 5(10.2)  
Normal with effort (80) 7(14.0) 7(14.3)  
Normal activity, minor signs/symptoms 
(90) 
12(24.0) 17(34.7)  
Almost normal (100) 20(40.0) 6(12.2)  
Total  50 49  
 
 
Comparison of symptoms prevalence by diagnosis 
The leading symptoms among the study groups were different and also, the differences in the 
prevalence of some symptoms were significant between the two groups (Table 12). In the breast 
cancer patients; pain (62.0%), worrying (44.0%), feeling sad (42.0%), weight loss (40.0%) and 
difficulty sleeping (38.0%) were the top 5 symptoms while in the gynaecologic patients, weight 
loss (67.3%), pain (65.3%), worrying (53.1%), feeling sad (51.0%) and lack of appetite (49.0%) 
were the top 5 . There were a number of additional symptoms which were not listed in the 
MSAS-SF but frequently described by the gynaecological cancer patients. These were mainly 
vaginal bleeding and discharge and they were actually the most frequent symptoms in the 
gynaecology patients (69.4%). 
Symptoms with significant differences in prevalence between the two groups were: weight loss 
(p= 0.006), lack of appetite (p<0.0001), hair loss (p<0.0001), change in taste (p=0.012), 
constipation (p<0.000), nausea (p=0.041), problem with urination (p=0.001), feeling bloated 
(p=0.031), and the additional symptoms 1 and 2, not listed in the MSAS-SF (p= 0.000, p= 
0.031).   
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Patients were asked whether they had additional symptoms and to mention these symptoms. The 
additional symptoms were different in the two study groups and they were frequently mentioned. 
In the breast cancer group, 16 patients mentioned additional symptoms 1: breast masses with or 
without ulcerations (7), breast discharges (1), chest discomfort (2), neck/axillary masses (2), and 
hoarseness of voice (1), muscle cramps (1), shivering (1) and amenorrhoea (1). Additional 
symptoms 2 were mentioned by 4 patients: abdominal discomfort (1), bed sores (1), breast 
wound (1) and immobility (1). Among the gynaecologic cancer group, 34 patients had one 
additional symptom: vaginal bleeding (18), vaginal discharge (7), abdominal swelling (3), gait 
problem (1), headache (1), vulva swelling (1) and continuous leakage of urine (1). Additional 
symptom 2 was mentioned by 12 patients: vaginal discharges (11) and discharging vulva sinuses 
(1).      
 
Table 12 Comparison of symptoms prevalence in the two groups 
Symptoms Breast n/50 Gynaecology n/49  Total n/99  p-value 
Pain 31(62.0%) 32(65.3%) 63(63.6%) 0.732 
Weight loss 20(40.0%) 33(67.3%) 53(53.5%) 0.006* 
Additional 1 16(32.0%) 34(69.4%) 50(50.5%) 0.000* 
#Worrying 22(44.0%) 26(53.1%) 48(48.5%) 0.367 
#Feeling sad 21(42.0%) 25(51.0%) 46(46.5%) 0.368 
Lack of energy 17(34.0%) 23(46.9%) 40(40.4%) 0.190 
Difficulty sleeping 19(38.0%) 21(42.9%) 40(40.4%) 0.622 
Lack of appetite 8(16.0%) 25(51.0%) 33(33.3%) 0.000* 
Numbness/tingling in hand and feet 13(26.0%) 16(32.7%) 29(29.3%) 0.467 
Don’t look like myself 11(22.0%) 14(28.6%) 25(25.3%) 0.452 
Cough  12(24.0%) 11(22.4%) 23(23.2%) 0.855 
#Feeling nervous 10(20.0%) 12(24.5%) 22(22.2%) 0.591 
Dry mouth 8(16.0%) 11(22.4%) 19(19.2%) 0.415 
Hair loss 18(36.0%) 0(0.0%) 18(18.2%) 0.000* 
Additional 2 4(8.0%) 12(24.5%) 16(16.2%) 0.031* 
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Shortness of breath 10(20.0%) 6(12.2%) 16(16.2%) 0.295 
Change in taste of food 3(6.0%) 12(24.5%) 15(15.2%) 0.012* 
Constipation 1(2.0%) 14(28.6%) 15(15.2%) 0.000* 
Dizziness 7(14.0%) 8(16.3%) 15(15.2%) 0.747 
Swelling of arms/legs 8(16.0%) 6(12.2%) 14(14.1%) 0.592 
Nausea  3(6.0%) 10(20.4%) 13(13.1%) 0.041* 
Sweats  9(18.0%) 3(6.1%) 12(12.1%) 0.121 
Problem with urination 0(0.0%) 10(20.4%) 10(10.1%) 0.001* 
Feeling drowsy 6(12.0%) 3(6.1%) 9(9.1%) 0.487 
Feeling bloated 1(2.0%) 7(14.3%) 8(8.1%) 0.031* 
#Feeling irritable 4(8.0%) 4(8.2%) 8(8.1%) 1.000 
Difficulty swallowing 3(6.0%) 4(8.2%) 7(7.1%) 0.715 
Vomiting 1(2.0%) 6(12.2%) 7(7.1%) 0.059 
Change in skin 4(8.0%) 1(2.0%) 5(5.1%) 0.176 
Itching 3(6.0%) 2(4.1%) 5(5.1%) 1.000 
Problem with sexual interest/activity 1(2.0%) 1(2.0%) 2(2.0%) 1.000 
Difficulty concentrating 1(2.0%) 0(0.0%) 1(1.0%) 1.000 
Diarrhea 0(0.0%) 1(2.0%) 1(1.0%) 0.310 
Mouth sores 0(0.0%) 0(0.0%) 0(0.0%) - 
# refers to psychological symptoms          * refers to significantly different symptoms (P-value 
less than 0.05) 
 
The topmost distressing symptoms in the two groups 
The highly distressing symptoms for the physical symptoms were those that were rated as “quite 
a bit’’ or ‘’very much’’, while psychological symptoms reported as ‘’frequently occurring’’ or 
‘’almost constantly occurring’’ are considered highly distressing. The most distressing symptoms 
for this study are those for which at least, 50% of the patients rated them as ‘’quite a bit/very 
much’’ and ‘’frequently occurring/almost constantly occurring’’ for physical and psychological 
symptoms respectively. Symptoms that were experienced by only 1 person in either group were 
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excluded from this analysis. These were constipation, feeling bloated, vomiting, problem with 
sexual activity/interest, difficulty in concentration and diarrhea.  
Table 13 shows the topmost 5 distressing physical symptoms for breast cancer patients.  ‘’Don’t 
look like myself’’ (72.7%) and pain (54.8%) were the highly distressing symptoms from the list 
of 28 physical symptoms listed in the MSAS-SF. The other symptoms rated as highly distressing 
were the additional symptoms (75.0%) not listed in the MSAS-SF and they include fungating 
breast masses or ulcerations, neck swelling and immobility. Swelling of arms/legs and some 
other additional symptoms were among the 5 leading most distressing symptoms but they 
occurred in less than 50% of those with the symptoms. All of the psychological symptoms were 
not considered highly distressing because all of them were rated as rarely or occasionally 
occurring. 
 
Table 13 The top five most distressing symptoms among breast cancer patients 
Symptom  Not at all/little bit (%) Somewhat (%) Quite a bit/Very 
Much (%) 
Pain  9 (29.0) 5 (16.1) 17 (54.8) 
*Additional 1 2 (12.5) 7 (43.8) 7 (43.8) 
Don’t look like 
myself 
1 (9.1) 2 (18.2) 8 (72.7) 
Additional 2 1 (25.0) 0 (0.0)  3 (75.0) 
*Swelling arms/legs 5 (62.5) 0 (0.0) 3 (37.5) 
*= among top five but not significantly distressing in up to 50% 
 
 
Table 14 shows the topmost distressing symptoms among the gynaecological cancer patients. 
The most distressing symptoms among the gynaecologic cancer patients for which >50% of the 
patients rated as ‘’quite a bit/very much were problem with urination (70.0%), don’t look like 
myself (64.3%), difficulty sleeping (57.1%), and pain (50.0%). The additional symptoms rated as 
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highly distressing (over 70.0%) included vaginal bleeding, vaginal discharge, abdominal 
swelling, vulva swelling, discharging sinuses and abnormal posturing.  All the psychological 
symptoms were also not rated as highly distressing. 
Table 14 the topmost distressing symptoms among the gynaecological cancer patients 
Symptom  Not at all/little bit (%) Somewhat (%) Quite a bit/Very 
Much (%) 
Pain  7(21.9) 9(28.1) 16(50.0) 
Additional 1  2(5.9) 7(20.6) 25(73.5) 
Difficulty sleeping 3(14.3) 6(28.6) 12(57.1) 
Don’t look like 
myself 
2(14.3) 3(21.4) 9(64.3) 
Additional 2 0(0.0) 1(8.3) 11(91.7) 
Problem with 
urination 
2(20.0) 1(10.0) 7(70.0) 
 
 
Symptom relief among the study population 
Symptoms relief or improvement was assessed after at least 7 days from the first contact. The 
period ranged from 7 -33 days with a mean duration of 8.86 + 3.5 days. A total of 8 patients were 
not reachable for the second contact. One died (a gynaecological cancer patient) before the 
minimum of 7 days required for contact while the remaining 7 (4 breast cancer patients and 3 
gynaecological cancer patients) were not reachable by phone or physical contact.  
Symptom relief or improvement resulting from usual treatments provided by patients’ usual 
attending physician was assessed. Some patients had been treated for symptoms such as pain 
with analgesics, all anemic patients had been transfused and some patients, especially the breast 
cancer patients had been commenced on chemotherapy before the time of second contact.  
Some patients reported new symptoms not mentioned at the first contact. The new symptoms 
included 3 new cases of pain, 2 new cases of lack of energy, a patient reported difficulty sleeping 
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and 2 patients reported diarrhoea. Three other symptoms were not listed in the MSAS-SF 
(vaginal discomfort, vaginal bleeding and yellowness of the eyes).    
Table 15 shows the comparison of relief or none relief of the symptoms assessed between the 
two groups of patients. Symptom relief was considered to be present when at least 50% of the 
patients with the symptom reported relief/improvement. There were poor symptom reliefs for the 
physical symptoms in most patients. Among breast cancer patients, 28 physical symptoms 
(excluding mouth sores and including the two individualized additional symptoms) were 
assessed for relief/improvement, only 4/28a symptoms: constipation, itching, problem with 
sexual interest and difficulty with concentration were reported as relieved by at least 50% of 
those affected. Gynaecological cancer patients on the other hand had 27 symptoms assessed 
(excluding difficulty in concentration and hair loss but including the individualized additional 
symptoms). Only 2/27b symptoms (dizziness and itching) were relieved in at least 50% of those 
with the complaint.       
The only 2 (feeling irritable and feeling nervous) out of the 4 psychological symptoms were 
relieved/ improved in at least 50% of those affected among breast cancer patients while less than 
a third(18-26%) of those with psychological symptoms were relieved/improved of their 
symptoms among the gynaecological cancer patients. The differences in relieve of all the 
symptoms between the two groups of patients was not statistically significant (p>0.05). 
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Table 15 Physical and psychological symptoms relief among the study populations. 
Symptoms Breast Cancer n (%) 
 
Gynaecological cancer n 
(%)  
 
P-
value 
Relieved Unrelieved Relieved Unrelieved 
Pain 10(33.3) 20(66.7) 8(27.6) 21(72.4) 0.632 
Additional 1 3(17.6) 14(82.4) 6(18.8) 26(81.3) 1.000 
Weight loss 0(0.0) 17(100.0) 1(3.3) 29(96.7) 1.000 
*Feeling sad 8(40.0) 12(60.0) 6(26.1) 17(73.9) 0.515 
*Worrying 8(40.0) 12(60.0) 6(26.1) 17(73.9) 0.515 
Lack of energy 3(16.7) 15(83.3) 5(23.8) 16(76.2) 0.702 
Difficulty sleeping 5(27.8) 13(72.2) 4(21.1) 15(78.9) 0.714 
Numbness/tingling in hand and 
feet  
5(45.5) 6(54.6) 4(26.7) 11(73.3) 0.419 
Lack of appetite 1(16.7) 4(83.3) 6(28.6) 15(71.4) 1.000 
Cough 3(25.0) 9(75.0) 0(0.0) 9(100.0) 0.229 
Don’t look like myself 0(0.0) 9(100.0) 1(9.1) 10(90.9) 1.000 
*Feeling nervous 4(50.0) 4(50.0) 2(18.2) 9(81.8) 0.319 
Dry mouth 1(12.5) 7(87.5) 1(10.0) 9(90.0) 1.000 
Hair loss 0(0.0) 17(100.0) - - - 
Additional 2 1(25.0) 3(75.0) 1(7.7) 12(92.3) 0.426 
Shortness of breath 1(11.1) 8(88.9) 1(16.7) 5(83.3) 1.000 
Change in taste of food 0(0.0) 2(100.0) 3(27.3) 8(72.7) 1.000 
Constipation 1(100.0) 0(0.0) 4(33.3) 8(66.7) 0.385 
Dizziness 2(33.3) 4(66.7) 4(57.1) 3(42.9) 0.592 
Swelling of arms/legs 1(14.3) 6(85.7) 1(20.0) 4(80.0) 1.000 
Sweats 2(25.0) 4(75.0) 1(33.3) 2(66.7) 1.000 
Nausea 0(0.0) 3(100.0) 2(28.6) 5(71.4) 1.000 
Problem with urination - - 0(0.0) 10(100.0) - 
Feeling drowsy 0(0.0) 5(100.0) 0(0.0) 2(100.0) - 
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Feeling bloated 0(0.0) 1(100.0) 1(16.7) 5(83.3) 1.000 
Difficulty swallowing 0(0.0) 3(100.0) 0(0.0) 3(100.0) - 
*Feeling irritable 2(66.7) 1(33.3) 0(0.0) 3(100.0) 0.400 
Vomiting 0(0.0) 1(100.0) 1(25.0) 3(75.0) 1.000 
Change in skin 0(0.0) 4(100.0) 0(0.0) 1(100.0) - 
Itching 2(66.7) 1(33.3) 1(50.0) 1(50.0) 1.000 
Diarrhea 0(0.0) 1(100.0) 0(0.0) 2(100.0) - 
Problem with sexual 
interest/activity 
1(100.0) 0(0.0) 0(0.0) 1(100.0) 1.000 
Difficulty concentrating 1(100.0) 0(0.0) - - - 
-a: breast cancer patients were not assessed for relieve of problem with urination, so had 28 
symptoms assessed for relieve 
-b: gynaecological patients were not assessed for relieve of hair loss and difficulty in 
concentrating, so had 27 symptoms assessed for relieve. 
*: Psychological symptoms 
 
The results of this study have shown the demographic distributions of the participants and 
comparisons made between the groups of patients. The effect of the educational status on the 
stage of disease and the duration of symptoms when the patients were interviewed were also 
highlighted. Peculiarities of gynaecological cancer patients with respect to treatment status in the 
study centre have also been brought to light as this differed from those of their breast cancer 
counter parts. 
The average number of symptoms based on the MSAS-SF used in both groups of patients has 
shown comparable results and differences have also been highlighted. Both study groups also 
had additional symptoms outside the scope of the symptom assessment tool used and these 
symptoms were entirely different. When these optional symptoms were considered along with 
those of the MSAS-SF tool, the difference in the overall symptom prevalence between the two 
groups became significantly different both in quantity and quality. 
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Changes in symptoms in terms of relief or worsening of symptoms were assessed at an average 
of 9 days after the initial contact. There was generally poor symptom relief among the study 
participants. The next chapter discusses the implications and explanations of all of the findings in 
further detail. 
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Chapter 5 
DISCUSSION 
This cross-sectional prospective study was carried out in order to explore and compare symptom 
prevalence among gynaecological and breast cancer patients in a tertiary health care institution in 
North Central Nigeria. This study is the first Nigerian study to prospectively survey symptom 
prevalence among breast and gynaecological cancer patients as well as make comparison 
between these groups of patients in this institution.  
Demographics 
Breast cancer occurs in age groups that tend to differ more with race than with settings (64, 65, 
170). Breast cancer is a postmenopausal disease among the whites in the developed countries but 
not so with blacks in the developing countries (43). A study by Bowen et al (170) reported an 
average age of 67 years among British white women while black Africa women have been 
shown to develop breast cancer in younger and premenopausal women with a significant number 
of them being in the active reproductive age group (1, 62,65). Anyanwu (43) in a ten year review 
of breast cancer in eastern Nigeria reported a mean age of 44 years and a peak age range of 35-
39 years. Adesunkanmi et al (62) also in their study reported a mean age of 48 years. Both of 
these studies have reported lower mean ages for the breast cancer patients than the 52.78 years 
that was obtained in this study. The reported mean age in this study is however much lower than 
that reported by Bowen et al. The peak age of 40-49 years obtained in this study was also similar 
to that obtained among the 212 patients studied by Adesunkanmi. The reasons for the lower 
mean age obtained in those other studies could be because of the larger sample size in those 
retrospective studies compared to this study.  
Patients with gynaecological cancers in this study were much older than the breast cancer 
patients. The mean age of 59.76 was slightly higher than 54 years reported by Nnadi et al (171)  
and 44.2 years reported by Kyari et al (172). Also apart from the larger sample sizes, these other 
studies encompassed a wider spectrum of gynaecological cancers which were not present in this 
study. The wide age ranges present in those studies were probably responsible for the lower 
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mean ages reported. The only three cancers captured in this study were cervical cancers, 
endometrial cancers and ovarian cancers. These other studies included choriocarcinoma, germ 
cell ovarian cancers, vaginal cancers, vulva cancers and fallopian tube cancers. These cancers 
incidentally were not seen during this study.  Except for cervical cancer which occurs commonly 
in women of similar age group as that of breast cancers, at about 35-45 years, ovarian and most 
especially, endometrial cancers are essentially postmenopausal diseases (27). Over 40% of 
gynaecological cancers in this study were ovarian and endometrial cancer patients. This may 
explain the higher mean age and peak age obtained for gynaecological cancers in this study. This 
study also involved only adult female and as such, some ovarian cancer that are commonly found 
in children and adolescents were excluded. These other studies included these juvenile cancers 
and again, this may explain the lower mean ages reported compared to this study.  The younger 
age of breast cancer patients compared to gynaecological patients could have implication for 
palliative or supportive care needs because of the effect of age on symptom experiences and 
distress. Younger patients with cancer tend to have more psychological problem than the older 
ones (173).  
 
Breast cancer patients were more educated than the gynaecological cancer patients with 50% of 
them having at least a secondary school level of education compared to gynaecological patients 
with only a third of them having same level of education. The high proportion of breast cancer 
patients with at least a secondary school level of education was similar to 48.7% found in study 
by Adesunkanmi et al (62). This is not surprising since breast cancers occur in younger age than 
gynaecological cancers, and younger patients are more likely to be educated than the older ones 
because literacy level is gradually increasing in Nigeria, like in other developing countries (43).  
Stage of Disease 
The TNM staging is used commonly for breast cancers while the FIGO staging is commonly 
used in staging gynaecological cancer, but the TNM system for gynaecological cancers is also 
available and it is similar to the FIGO staging but with some subtle differences(174). Comparing 
breast and gynaecological cancers stage for stage is based on the general classification of stage 1 
and 2 cancers as early cancers and stages 3 and 4 as late or advanced cancers (98,175). It is 
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acknowledged that the sub-classifications within each of the stages are of significant prognostic 
as well as therapeutic implications which may in turn affect symptom elaborations.  
An advanced stage of disease at presentation to hospital, as was found in this study, is very 
common for many cancers in the developing countries (43,44), including cancers of the breast 
and cervix which are easily accessible organs for early detection of cancer (176). More than 80% 
of patients in both groups were at stage 3 or 4 of their disease based on their different systems of 
their tumour staging. This conforms to previous studies (1,2,43,74,78) in Africans that have 
shown that patients present in advanced stages of cancer.  
The generally advanced stage of presentation of patients in this study was worse among the 
gynaecological cancer patients than the breast cancer patients in this study. One-fifth of breast 
cancer patients had early disease (stage 1 or 2) while only one-tenth of gynaecological cancer 
patients had stage 2 disease and none had stage 1 disease. The younger ages and the higher 
educational statuses among the breast cancer patients may have accounted for this little 
difference. When stages of diseases were compared with the educational status, patients with 
lower educational levels presented at more advanced stages of diseases than the educated 
patients. Some studies (2,77) in cancer patients have also reported more advanced stages of 
disease in patients with lower socio-economic class. However, among the educated patients, a 
higher proportion of those with tertiary level of education actually presented at more advanced 
stage disease compared to those with secondary level of education. This may imply that higher 
educational status does not result in early presentation to hospital. This was similar to the 
findings by Anyanwu (66) who reported similarly advanced stage of disease in their population 
of highly literate patients managed for breast cancer. Poor knowledge about cancer both by the 
educated and the uneducated people, even among health care providers have been reported by 
some authors (177). Attributing cancer to sorcery and witchcraft is believed by some people and 
this include both literates and illiterates (43,66). Cancer screening centre are also scarce in many 
African settings, including Nigeria (46) and the available once are poorly maintained and 
underutilized (2,59). All these contribute to late presentation of cancer cases to the hospital. 
Continuous public enlightenment by providing accurate information and embarking on 
awareness campaigns on cancer, training and retraining of health care providers, creating more 
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cancer screening centres as well as renovating the existing ones are needed in order to reduce the 
number of patients presenting in advanced stage of disease. 
 
Duration of disease 
The duration of disease in this study was based on time recollection by the patient. This may be 
affected by recall bias as individuals differ in their ability to correctly recall events. Patients with 
difficulties were aided by relating onset of disease with important festive periods and those on 
treatment were able to relate the duration on treatments to the duration of their disease. The 
duration of disease in both groups though appeared not to be significantly different, about 75% 
of gynaecological cancer patients were within 12 months of their disease compared to only 56% 
of breast cancer. By the third year of disease, fewer gynaecological patients were still accessing 
care compared to the breast cancer patients.  
The median duration of symptoms of the disease at first interview had always been longer for 
breast cancer patients than for gynaecological cancer patients. Almost half (48.9%) of 
gynaecological cancer patients were seen within 6 months of onset of their disease while about a 
quarter (26.0%) of breast cancer patients were seen within the same period of time. This may be 
because gynaecological cancer patients experience more severe symptoms or more distressing 
symptoms compared to the breast cancer patients and these make them seek care earlier. It may 
also be that gynaecological cancers progress more rapidly than breast cancers, resulting in rapid 
deterioration in overall well-being, forcing them to seek care earlier. In contrast to short interval 
from cancer symptom occurrence to accessing care seen in gynaecological cancer patients, breast 
cancer patients had remained on treatment/follow up for longer periods of time than the 
gynaecological cancer patients. Forty-four percent of breast cancer patients were still accessing 
care more than a year after their first presentation to the hospital while only 24.5% of 
gynaecological cancer patients were still coming to access care. The main reason for this was 
because the breast cancer patients normally are prescribed hormonal therapy which is maintained 
for 5 years after the initial surgery and chemotherapy/radiotherapy. Treatment protocols in 
gynaecological cancers commonly do not normally involve such prolonged hormonal therapy. 
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Also, since gynaecological cancer patients were much older, there is the possibility of them 
dying from old age or other age related conditions than the younger breast cancer patients. 
 
 
Cancer treatment 
Cancer treatment is a major problem in many African countries and this was also demonstrated 
in this study. Thirty percent of breast cancer patients in this study were not on anticancer 
treatment as at the time of first interview while over 90% of gynaecological patients also were 
not on any anticancer treatment. Among the breast cancer patients, financial constraints was the 
reason for none commencement of chemotherapy among 5 patients, 6 patients were experiencing 
delays before surgery while 4 patients were being managed for severe anaemia/respiratory 
distress and were yet to commence anticancer treatments. Gynaecological cancer patients are 
usually treated with surgery for operable cases and then have subsequent courses of 
chemotherapy or radiotherapy. Gynaecological cancers that are inoperable or that require 
additional therapy after initial surgery are referred for radiotherapy. Cervical cancer constituted 
more than 50% of the gynaecological patients in this study and many of them presented in 
advanced stage of disease for which radiotherapy referrals were made. Advanced stage at 
presentation for cervical cancers in the developing countries continues to occur in spite of 
cervical cancer being preventable through regular screening using papsmear or visual inspection 
of the cervix with acetic acid. The addition of Human Papilloma Virus vaccine to the preventive 
strategies in the recent past is expected to further reduce the incidence of cervical cancer (178). 
Screening for cervical cancer allows early detection of the disease at a stage when cure can be 
achieved and treatments are simple and affordable. Advanced cervical cancer requires 
chemoradiation in addition to complex cancer surgeries which are not readily available in many 
developing countries, including Nigeria (3,47)). Endometrial cancer patients are also usually 
referred for radiotherapy after initial debulking surgery. This very common referral of 
gynaecological cancer patients for radiotherapy outside the state may explain the fewer number 
of gynaecological patients still accessing care after one year of diagnosis. It is not always 
ascertained whether patients sent for further treatments like radiotherapy do report for such 
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intended therapy or not because funds are constantly a limiting factor in patients’ management in 
this environment (60). As illustrated by Anyanwu et al in their study, many patients out rightly 
decline treatments while some that accept may not be able to continue due to cost as well as the 
inconveniences of travelling for radiotherapy outside their location of residence (66). Also 
contributing to fewer gynaecological cancers patients still accessing care long after their initial 
diagnosis is the fact that many patients do not report back for follow up even after completing 
the treatment for which they were referred. Other studies have also reported significant loss to 
follow up among cancer patients (62). The radiotherapy referral of gynaecological cancer 
patients is of great concern because there are very few number of radiotherapy machines in the 
country presently and they are not always in good functional states (2) yet patients are being 
referred continuously because that is the only feasible anticancer treatment for some patients. It 
is not known if these referred patients actually ever get to their destination or even receive the 
prescribed radiotherapy. This problem with radiotherapy referral was demonstrated in this study 
as more than 20% of gynaecological cancer patients were already referred but all were yet to go 
for financial reasons as well as lack of information on the functionality of the radiotherapy 
centers. The nearest radiotherapy facility to the study facility is about 3 hours drive away and it 
was not functioning at the time of this study. The other radiotherapy facilities were much further 
away and there was no ready information on their functionality.  Another 30% of gynaecological 
cancer patients were still being evaluated at the time of the study; all were cervical cancer 
patients and were likely to end up being referred for radiotherapy as well. All the three 
gynaecological cancer patients that had received radiotherapy in this study all had cervical 
cancer and all were referred to the palliative care team by their primary physicians because there 
were no further anticancer treatments available for them. Their palliative care referral was 
indicative of the palliative intent of the radiotherapy treatment they had received. 
Symptom Prevalence 
The prevalence of symptoms in this study ranged from 0 – 18. This was lower than a range of 0 -
25 reported by Portenoy et al(179) but comparable to 1 -18 symptoms reported by Tsai et al(180) 
both of which were studies conducted in similar cancer population to this study.  About 20% of 
patients in this study had 0 or 1 symptom only. The heterogeneity of patients in terms of stages 
of disease and treatment statuses could explain the widely differing symptom prevalence. 
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The overall mean number of symptoms was based on the symptom assessment tool used with 
limited availability for inclusion of additional symptoms not enlisted in the tool. The overall 
mean number of symptoms was 6.9 + 4.7 and the median was 7 symptoms in this study. The 
result is comparable with that obtained for a cancer population studied in London (129) but it 
was much lower than that reported in a similar group of patients studied in Africa (6). 
Considering the additional symptoms was important in this study because some patients, 
especially the gynaecological cancer patients had none of the 32 symptoms listed in the MSAS-
SF tool and the additional symptoms were the only symptoms documented for them. Such 
gynaecological cancer patients had only vaginal bleeding and foul smelling vaginal discharge as 
their only symptoms. In considering the additional symptoms, the mean number of symptom for 
breast cancer patients was 5.8 and that of gynaecological cancer patients was 8.1. This difference 
in the mean number of symptoms was significantly different between the two groups of patient 
with the gynaecological cancer patients having more symptoms which can be attributed to 
additional symptoms not listed in the MSAS tool. These mean numbers of symptoms were much 
lower than 18 + 6.6 reported by Harding et al (6) and also 10.2 + 5.8 reported by Lidston et al 
(181). It was however slightly higher than the overall mean of 5 symptoms reported by Potter et 
al (120). Harding et al (6) study was conducted in patients already referred for palliative care 
intervention, signifying advanced cancer in all of their patients, and this alone may explain the 
higher mean number of symptoms. Also, patients with HIV infection also constituted a 
significant proportion of Harding et al study population and this also may explain the higher 
number of symptoms in their study population. HIV infection itself is associated with significant 
psychological and physical symptoms due to its multi-systemic effects (149). Although HIV was 
not the focus in this study, three of the patients had HIV infection documented in their case 
notes. But these three are much lower in comparison to the number of HIV infected patients in 
Harding’s study. The lower mean number of symptoms obtained in this study compared to that 
of Harding et al (6) may also be due to additional symptoms which were eight in number, 
incorporated into the MSAS-SF used in that study compared the optional one or two additional 
symptoms that was added if present in this study.  
The study by Lidston et al (181) was a mixture of both early and advanced cancer patients 
attending clinics at a cancer center and this was similar to this study population in this regard. 
The lower mean number of symptoms obtained in this study compared to that of Lidston et al 
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(181) could be explained by the other cancer sites that were represented in that study. These 
included lung, brain, head/neck and gastrointestinal cancers in addition to breast and 
gynaecological cancers. Lung and brain cancers had the highest number of symptoms in that 
study, followed by breast, gastrointestinal and head/neck cancers.  Gynaecological cancers were 
among cancers with the least number of symptoms in Lidston’s study. 
The patients in Potter et al (120)  study were freshly referred to palliative care services and just 
over 70% of them had advanced cancer, making it comparable to this study population in whom 
about 80% of them also had advanced cancer. Potter’s study consisted of patients that were seen 
in 4 different settings. Those in the outpatient and inpatient settings actually had lower mean 
number of symptoms of 3.3 and 2.7 respectively. Patients seen at the hospice and community 
service points had higher mean number of symptoms of about seven. Comparing the outpatient 
and hospital inpatients that were of similar setting to this study population, the mean number of 
symptoms in Potter’s study was much lower than that obtained in this study. It is possible that 
the retrospective nature of Potter’s study with the high probability of under-reporting and under-
documentation of symptoms may have accounted for this lower symptom prevalence.     
The overall ten most frequent symptoms in this study were pain, weight loss, worrying, feeling 
sad, lack of energy, difficulty in sleeping, lack of appetite, numbness/tingling in hand and feet, 
‘’don’t look like myself, and cough. Comparing these with the top 10 most prevalent symptoms 
in a systematic review by Kim et al (94) and Reily et al (182), 6-8 of these symptoms were 
replicated in this study. Also, Teunissen et al’s (95) top five symptoms of fatigue, pain, lack of 
appetite, weakness and anorexia are similarly found in this study. The symptoms reported in this 
study correlated well with finding from other studies that have used similar symptom assessment 
tool. 
Common symptoms in this study  
The top 5 most prevalent symptoms between the two study groups were similar but different in 
sequence. For breast cancer patients, pain, worrying, feeling sad, weight loss and difficulty 
sleeping were the top 5 symptoms. The top 5 symptoms for gynaecological cancer patients were 
weight loss, pain, worrying, feeling sad and lack of appetite. Four of these top five symptoms 
that were common to both study groups occurred in higher frequencies among the 
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gynaecological patients.  Both the gynaecological cancer patients and breast cancer patients 
reported pain and weight loss as the most common physical symptoms while feeling sad and 
worrying were the two most prevalent psychological symptoms reported. Similar symptom 
prevalence studies on breast and gynaecological cancer patients by Aeckerle et al in Germany 
(108) reported on weakness, pain and anorexia as the most common symptoms in their study 
population of 225 patients. Other notable symptoms in Aeckerle et al’s (108) study were 
dypnoea, nausea/vomiting. The symptoms reported by Aeckerle et al’s (108) study were mainly 
physical symptoms extracted from medical records and this may explain the limited number of 
symptoms as well as the absence of psychological symptoms. A similar study in Ibadan, Nigeria 
(109) reported on pain, vomiting, nausea, weight loss and lymphedema as the top 5 and similarly 
prevalent symptoms in breast and cervical cancer patients. Here again, the study was 
retrospective in nature and symptoms reported on were just the symptoms documented in the 
medical records and psychological symptoms were absent. Studies have shown that 
psychological symptoms are commonly overlooked in patients with advanced cancer (183). This 
study has shown that with the use of a symptom assessment tool that ensures questioning about 
psychological symptoms, they have been shown to be quiet prevalent.  Almost all of the patients 
had been under the care of their attending physicians for several weeks/months before being 
recruited for this study. All had clinical diagnosis of cancer, some were currently on treatments, 
some had completed available anticancer treatments, others were awaiting commencement of 
treatments and some were being referred for radiotherapy. Forty percent of the top most common 
symptom in this study was psychological symptoms, yet none of the patients had any 
psychological nor psychiatrist referral or evaluation. Only 11% of the patients had palliative care 
referral. This shows that psychological symptoms assessment needs to be incorporated into the 
evaluation of breast and gynaecological cancer patients in this hospital. Many oncologists agree 
that palliative care should be incorporated into comprehensive cancer care at the point of 
diagnosis, many also claim to be rendering palliative care already, but evidence show that it is 
either not done at all or it is inadequately done (184). This is an important information for the 
primary physicians in this hospital who most of the time manage these cancer patients alone 
without the involvement of the palliative care team or psychiatrist/psychologists. 
This study revealed that breast and gynaecological cancer patients significantly differed with 
respect to certain symptoms. Gynaecological cancer patients had higher frequencies of symptoms 
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that are related to gastrointestinal and urinary systems compared to breast cancer patients. The 
proximity of the gynaecological organs to these systems may account for many of the symptoms. 
Breast cancer patients conversely had chest symptoms such as cough and shortness of breaths 
more commonly than in the gynaecological cancer patients. These findings are similar to that 
reported by Lidston et al in their study. Although not statistically significant, gynaecological 
cancer patients had higher frequency of psychological symptoms than the breast cancer patients. 
This contrasts the finding in other studies that have reported higher occurrence of depressive 
symptoms among breast cancer patients compared with gynaecological cancer patients 
(181,183). Also in contrast to findings in other studies that have reported higher frequency of 
psychological symptoms in younger age women (173), breast cancer patients in this study were 
younger than the gynaecological patients, yet, psychological symptoms were more in the 
gynaecology than the breast cancer patients. While this may be a genuine finding in our 
environment, the fact that many of the gynaecological cancer patients were inpatients, had higher 
frequencies of the presence of additional symptoms and also had worse performance status 
scores may explain this higher frequency of psychological symptoms in them. More than two-
thirds of the gynaecological cancer patients had notable additional symptoms that were not 
captured in the 32 symptoms listed in the MSAS-SF. In contrast to this observation, only one-
third of breast cancer patients had additional symptoms not already listed in the MSAS-SF. 
Breast cancer patients had hair loss exclusively in them. This reason for this was because many 
of them were on chemotherapy while gynaecological patients were either awaiting or had 
completed chemotherapy at the time of the study. The symptom list in the MSAS-SF seems to 
adequately cover chemotherapy induced symptoms. This finding in this study shows that the 
present symptom list in MSAS tool may be adequate for symptom assessment in breast cancer 
patients for this environment but may require modifications in order to adequately accommodate 
gynaecological cancer patients’ symptom profiles. The symptoms for which breast and 
gynaecological patients significantly differed in this study are noteworthy for palliative care team 
who see all cancer patients of different diagnoses. The palliative care team is usually called in to 
co-manage patients with uncontrolled pain in this hospital. The reported symptoms from this 
study represent additional symptoms that the palliative care team could enquire about, pending 
the availability and acceptability of an assessment tool in the routine care of patients in this 
hospital.  This prior knowledge of the common symptoms of these groups of cancer will help to 
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guide patients’ management and inform other supportive measures that will help to improve care 
and quality of life for the patients. 
Most Distressing symptoms 
The multidimensional measurement of symptoms made possible by the use of MSAS makes it 
easy to be able to identify the most distressing symptoms in the list of symptoms while the 
MSAS subscales also helps to categorize the type of distress by assessing the scores obtained 
from a constellation of some specific symptoms. The mean GDI, MSAS-PHYS, MSAS-PSYCH 
and TMSAS in this study were all low compared to other studies assessing these scales. The 
mean GDI of 0.76 + 0.68 obtained in this study was much lower than 1.61 and 1.74 obtained by 
Richard et al(149) and Harding et al(6) in their studies and still lower than 1.3 reported by 
Portenoy et al(179). The study by Harding et al involved HIV positive patients already 
committed to palliative care while the second study, although done on cancer patients had one-
fifth of the study population having HIV diagnosis unlike this study where only 3% had HIV 
diagnosis. Both of Harding’s studies were conducted in patient populations in the palliative care 
settings, signifying advanced diseases in all of the patients. This may explain the higher GDI 
scores in these studies compared to my study. Portenoy’s study was done on cancer population 
similar to this study with respect to inpatients and outpatients at various cancer stages in a 
hospital setting and not necessarily palliative care setting. The higher GDI in Portenoy’s study 
also may be due to wider cancer populations involving colon and prostate cancer and the fact that 
over 60% of that study population was those with metastatic disease (stage 4) unlike this study 
where only 20% of the study population had stage 4 diseases. It may also indicate that current 
management is taking care of most of these symptoms and that specialist palliative care referral 
is not necessary. 
Similarly, the mean scores for MSAS-PHYS of 0.58 + 0.6 and MSAS-PSYCH of 0.75 + 0.78 
reported in this study were also much lower compared to the above studies that have reported on 
these MSAS sub-scale scores. Again, the HIV status, the palliative care settings and the higher 
proportion of patients with metastatic diseases as earlier highlighted may explain the higher 
scores ranging between 0.9 – 1.48 for MSAS-PHYS and 1.1 – 1.56 for MSAS-PSYCH reported 
in the above mentioned studies.  
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This study however revealed differences in the two study groups. The MSAS-PHY and the GDI 
show that the gynaecological cancer patients were both physically and globally more distressed 
than their counterpart breast cancer patients. Again, this may probably be a reflection of the 
higher frequency of symptoms in them. The Karnofsky Performance Score which is also closely 
related to the presence of symptoms was also lower in the gynaecological patients, implying 
possibly more distress in the gynaecology patients. The most distressing symptoms for breast 
cancer patients were feeling bloated, vomiting; don’t look like myself and pain. Other symptoms 
rated as most distressing were not listed in the MSAS tool and included presence of fungating 
breast masses, neck swelling and immobility. Gynaecological cancer patients similarly had body 
image issue and pain as most distressing as in the breast cancer patients but also in addition, had 
problems with urination, difficulty sleeping, vulva swelling, vaginal bleeding, vaginal discharge, 
abdominal swelling and abnormal posturing as most distressing too. “Don’t look like myself” 
which connote a body image issue and pain were the two symptoms that cut across this study 
population as most distressing. Pain has similarly been reported in many studies to be very 
distressing and results in aggravation of other symptoms. Any mutilating surgery is also likely to 
result in a sense of poor body image in any patient. For the breast cancer patients in this study, 
mastectomy and the presence of huge fungating breast masses constituted disfigurement which 
resulted in poor body image in these patients. Among the gynaecological patients, weight loss 
and body swellings were the reasons for poor body image. A sense of poor body image 
negatively affects sexuality and sexual function (185,186). For many women, the breast is 
considered an important component of womanhood and loss of it negatively affects the physical 
appearance as well as the psyche of most women (186,187). Chemotherapy also contributes to 
reduction of sexual function by inducing menopause or worsening menopausal symptoms for 
those that are already menopausal (185). Gynaecological cancer survivors in developed countries 
commonly encounter post treatment sexual dysfunction arising from surgical procedures or 
pelvic radiotherapy (185). The reasons for sexual dysfunction in this environment are quite 
different because of late presentation of cancer which commonly precludes such extensive 
surgical interventions as well as poor accessibility and affordability of radiotherapy facilities. 
Nearly half of the gynaecological cancer patients in this study were having vaginal bleeding and 
or foul vaginal discharge which in themselves were impediments to sexual relations. The only 
three gynaecological cancer patients that had received radiotherapy were severally ill from their 
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cancers were all referred to palliative care team for end-of-life care. Although almost all the 
patients in this study claimed not to have any problem with sexual relation or interest as it was 
stated in the MSAS-SF, majority of them actually do not consider sexual relationship a priority 
in their present predicaments of battling with cancer diagnosis. Despite asking with much 
sensitivity and caution, some of them were still offended and other embarrassed by the 
questioning. It may be more appropriate to find ways to identify patients that will be willing to 
discuss sexual issues and who may then require advice in this regards other than asking very 
patient this sensitive question. This is especially so in this environment where sexual issues are 
not commonly discussed openly (188).  
All the psychological symptoms were not considered distressing by both gynaecological and 
breast cancer patients and there was no difference between the two groups with respect to the 
psychological MSAS subscale (MSAS-PSYCH). The low distress caused by the psychological 
symptoms may be responsible for the non-treatment in spite of the high prevalence. The 
possibility of under-reporting of the distress caused by psychological symptoms may be due to 
more focus on physical symptoms, especially if they are severe. The low scores for 
psychological symptoms reported in this study may also be attributed to poor understanding of 
cancer as a disease among the populace (189,190). Other studies have highlighted that poor 
cancer knowledge is common to both literates and the non literates (54)(66). Among the literates 
and those with the knowledge of the life threatening nature of cancer, the influences of culture 
and religion may tend to override the knowledge (191,192) and this may account for the low 
level of psychological distress reported in this study. The high prevalence of psychological 
symptom though with low level of distress is a pointer to the need for repeated or close 
psychological monitoring as the disease progresses or as the patients understand their illness 
better. 
Symptom Relief 
Symptom relief in this study was assessed by an average of 8 days after the initial interview. The 
heterogenous cancer stages and treatment statuses was a possible bias to this assessment. Also, 
the average of 8 days interval between the assessments may be too short, especially for those that 
were yet to commence treatment. 
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Relief of symptoms was not different between the breast and gynaecological cancer patients in 
physical symptoms that were common to both groups. The breast cancer patients were assessed 
for relief of 28 physical symptoms but relief was noted for only 4 symptoms- constipation, 
itching, problem with sexual interest and difficulty in concentration. Gynaecological cancer 
patients were assessed for relief in 27 physical symptoms and relief was documented for only 
two symptoms which are dizziness and itching. Generally, more symptoms were relieved among 
the breast cancer patients than the gynaecological patients. Pain was the most prevalent symptom 
in this study with a rate of 63.6%, and pain relief was reported in only one-third of the patients 
with the complaint of pain. Although pain management is almost the only major reason for 
palliative care referral in this hospital, not all patients with pain were referred. While it is not 
only palliative care providers that can manage pain, they are more likely to do it better than 
physicians without palliative care experience. This is because palliative care providers 
holistically approach symptom management in life threatening diseases and are more likely to 
treat pain using the concept of total pain. 
 Psychological symptoms though not considered to be significantly distressing, were also poorly 
improved among the study population. All the psychological symptoms of feeling sad, worrying, 
feeling irritable and feeling nervous were not improved at second contact in majority of 
gynaecological cancer patients (73.9-100%). Breast cancer patients also had at least half of them 
not relieved of feeling sad, worrying and feeling nervous. Feeling irritable was much improved 
among the breast cancer patients at the second contact. This study has shown high prevalence of 
psychological symptoms which did not improve overtime. This further emphasizes the need for 
psychological assessments and interventions in addition to the present routine care being offered 
to breast and gynaecological cancer patients in this center. It is only a holistic approach to care 
that can bridge this gap. The holistic approach is the hallmark of palliative care and was shown 
to be lacking in the care of majority of these patients. Referral for a palliative care consultation 
for this study population was generally poor considering the advanced stage of disease in most of 
the patients as well as the high prevalence of symptoms reported in this study. The present 
practice in this hospital is for the palliative care team to be invited to help co-manage poorly 
controlled pain only and occasionally and at the discretion of the managing physicians, and also 
to help co-manage patients at the end-of life. The fact that cancer patients have life-threatening 
conditions for which palliative care needs to be applied right from the point of diagnosis and 
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along with active anticancer treatments is not yet well appreciated by many physicians in this 
hospital. As at the time of this study, only 6% of breast cancer patients and 16% of 
gynaecological cancer patients had palliative care referral evident in their case notes. More 
gynaecological cancer patients were referred for palliative care than the breast cancer patients, 
probably because of inpatient status that was commoner with the gynaecology patients and also 
the poorer performance levels of these patients as was earlier mentioned.     
Conclusion 
This study has shown that breast and gynaecological cancer patients in this hospital do have 
significant symptoms that are poorly addressed. The paucity of funds to commence and maintain 
treatments and outright non availability of some other anti-cancer treatments all contribute to 
disease progressions and worsening of symptom burden. These are pointers to the need for   
palliative care in the majority of patients accessing care in this hospital. The poor relief of 
symptoms noted in this study is therefore not unexpected. If this trend continues, it will pave way 
for patients’ and their families’ dissatisfaction with the health care services and it will lead to 
distrust of the health care systems, which further pushes patients away from seeking care early. 
A possible way of forestalling this situation is to integrate palliative care into the care of these 
patients at every available service point and early in the course of their disease. Studies (159,193, 
194) have shown that palliative care involvements in patients’ care improve symptoms control 
and also patients’ and their families’ satisfaction. These interventions have been shown to be 
effective in various settings including hospital-based inpatient care (193), home-based care 
(196), community settings as well as outpatient settings (120). There is the need for the primary 
physicians attending to cancer patients to be trained in palliative care. This would improve their 
understanding of palliative care so that they can also implement palliative care earlier and also 
refer for specialist palliative care services when necessary. Advocacy for patients to be referred 
for palliative care is the right thing to do, but the limited availability of palliative care specialists 
in the country is also well known (197). The present palliative care team in the hospital has 
limited capacity to cater for the load of patients requiring palliative care. An interim solution will 
be for the primary physicians to be trained in general palliative care pending the widespread 
availability of specialist palliative care providers.       
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Limitation of the study 
This study was a hospital based study and as such the findings may not be generalized to the 
whole community. 
Symptom assessment as well as its relief was assessed across board and the patients varied in 
stage of diseases and treatment status with some having completed anti-cancer treatment while 
some were currently on treatment and others were yet to commence treatments. The varied 
stages of diseases and treatment status within and between the studied groups may have had an 
effect on symptom prevalence and actual relief as well as perception of relief in some patients. 
Also, treatment interventions could not be assessed in detail because it was not known if the 
patients mentioned their symptoms to their attending physicians. 
The 8 days interval for symptom re-assessment was also short, especially for patients that were 
yet to commence anti-cancer treatment  
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CHAPTER 6 
CONCLUSIONS AND RECOMMENDATIONS 
CONCLUSIONS 
The aim of this study was to assess and compare the prevalence and burden of symptoms among 
breast and gynaecological cancer patients accessing care at the University of Ilorin Teaching 
hospital, Ilorin, Nigeria. This was accomplished with the aid of a symptom assessment tool, the 
MSAS-SF. The objectives of the study were to determine the most prevalent symptoms, the most 
distressing symptoms as well as assess symptom relief among the two groups of patients. The 
performance status of the patients were also assessed and compared between the groups of 
patients. 
Both the breast and gynaecology cancer patients described pain, weight loss, worrying and 
feeling sad as the top 4 symptoms similarly in them albeit of different order.  Fifty percent of 
these were psychological symptoms (worrying and feeling sad) while the remaining 50% were 
physical symptoms (pain and weight loss). This further reaffirms the high prevalence of 
psychological symptoms and that it may be as important as physical symptoms in cancer 
patients. 
The finding shows higher symptom prevalence among the gynaecological cancer patients than 
the breast cancer patients. Gynaecological patients also had higher frequencies of urinary and 
gastrointestinal symptoms than breast cancer patients who also in turn had higher frequency of 
chest symptoms such as breathlessness and cough more frequently than the gynaecology 
patients.   
Comparatively, gynaecology patients were more globally (GDI) and physically (MSAS-PHYS) 
distressed than the breast cancer patients. However, both groups were comparable with respect to 
psychological distress (MSAS- PSYCH).           
Although the study was not interventional as patients received routine care from their managing 
physicians, there was poor relief of symptoms among majority of the patients studied. 
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This study have shown that breast and gynaecological cancer patients do have significant 
physical and psychological symptoms, some of which are quite distressing and the relief of many 
of the symptoms were equally suboptimal. This shows an unmet need for symptom assessment 
as well as symptom control in these groups of patients.  
 
RECOMMENDATIONS 
Advanced stage of disease at presentation in majority of the patients in this study is a reflection 
of poor knowledge about cancer in many of the patients and also poor cancer screening services 
that can help detect early stage diseases that are simpler and less costly to manage. This is a call 
to action for all those responsible for cancer care and control to further intensify or develop other 
strategies that would result in prevention and early detection of cancers. 
The study revealed a high symptom prevalence, poor symptom relief as well as poor palliative 
care referral of breast and gynaecological cancer patients. It has been advocated that palliative 
care should be introduced early in the course of cancer care, but this becomes more imperative 
for those presenting in advanced disease for which treatment intent is palliative right from the 
point of diagnosis. The infrequent palliative care referral by the managing physicians in this 
study points to poor knowledge and understanding of palliative care among health care providers 
currently managing these patients. It is recommended that the physicians managing these patients 
should be educated on palliative care so that they can learn to introduce such care early in the 
course of managing their patients. This is also a recommendation of the World Health Assembly 
Resolution on strengthening palliative care as a component of comprehensive care throughout 
the life course which states that intermediate training in palliative care “should be offered to all 
health care workers who routinely work with patients with life-threatening illnesses, including 
those working in oncology” (198). 
It is suggested that protocols are developed to help guide the physicians as to when to consider 
palliative care involvement in both early and late staged cancer patients since the transition from 
curative treatment to palliative treatment is not always clear cut. 
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Poor symptom assessment and subsequent poor symptom relief as shown in this study indicates 
need for adequate symptom assessment. It is recommended that the clinics should adopt any of 
the available validated symptom assessment tools or develop their own tool to capture the 
common symptoms peculiar to their cancer sub-populations. The development of cancer site-
specific symptom assessment tool is particularly more relevant for gynaecological cancer 
patients in this environment because this study has shown that gynaecological cancer patients 
had significant symptoms that were not enlisted in the symptom assessment tool that was 
adopted for this study. It is also recommended that the validated tools available now such as 
ESAS, MDASI and MSAS should also be validated in Nigeria for possible adoption in managing 
cancer patients.         
The adoption of a symptom assessment tool in itself is not enough because its implementation is 
equally important. The crowded and multi-specialist clinics’ running simultaneously as it is 
presently the case may make implementation very difficult. There is therefore the need to also 
train other clinic staff especially the nurses that organize the clinics, on the use and need for the 
symptom assessment tool to be adopted. There is also the need for patients to be educated on the 
use and benefits of the tool in order to encourage acceptance on the part of the patients. 
Further studies on how best to implement a symptom assessment tool in typical busy hospitals 
that characterize many developing countries like Nigeria is highly needed. 
This study has also highlighted the high prevalence of psychological symptoms which were not 
assessed nor relieved. This also calls for re-education of the managing physicians on the need for 
routine psychological assessment or screening of cancer patients. Such screening will allow 
involvement of psychologist or psychiatrist either alone or in conjunction with a palliative care 
team in the care of patients needing such specialist care.  
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 APPENDIX I 
 
Information Sheet for:  
An Exploration of symptom burden among breast and gynaecological cancer patients 
accessing care at the University of Ilorin Teaching Hospital.  
 
 
Thank you for giving your time to hear about our research study.  
This information sheet tells you about a research study that you may wish to take part in. You 
may have some further questions to help you decide whether you want to take part. You can ask 
any further questions from your clinical team, from the researcher, or using the telephone 
numbers at the end.  
Thank you for thinking about whether you want to take part. Please take your time to make a 
decision. 
What is the purpose of the study? 
We are looking at the symptoms experienced by breast cancer and gynaecological cancer 
patients and checking if these symptoms are well noted and being treated by the attending 
doctors. 
 
Do I have to take part? 
No, you don’t have to take part. If you do agree to take part, you are free to withdraw from the 
interview at any time without giving us any reason.  Whether or not you take part, your care will 
NOT be affected in ANY WAY. If you do agree to take part, you will be asked to sign a consent 
form, which shows that you have agreed to do so. You can take some time to think about 
whether you would like to take part, and you may want to talk it over with your family, friends 
or someone in your care team.  
 
What will happen if I take part? 
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An experienced researcher will speak to you and ask you questions about you and your health, 
and this may include any pain or other problems you have and how well they are been controlled. 
It will take around 15-20 minutes for the interview. We will need to check your hospital case 
notes for further information on your disease and the treatment your doctors have planned for 
you or that they are already giving you. This will take 10-20 minutes and we may check your 
case note before speaking to you or vice versa. The checking of the case note is not part of the 
time we need to spend with you.   This information sheet is for you to keep.  
 
Benefits of the study 
There are no direct benefits to the study for participants although people who have been 
interviewed using these questionnaires find that they are good points for discussion with care 
providers. The anticipated benefits are in identifying people’s care needs and in trying to meet 
those needs.  
 
What are the risks of the study? 
There are few study risks. Answering some questions might cause an emotional response. The 
researchers and counselors are trained to assist if the questions cause an emotional response. The 
researcher will stop the study and ask you if you would like assistance 
 
Will my taking part in this study be kept confidential? 
All the information which we collect during the interview will be kept strictly confidential. You 
will not be identified in any way, and your personal details (for example name and address) will 
be kept separately from the information you give. We will use a number and not your name on 
any information you give us. No-one outside the study will have access to the information you 
give us.  
For patients in this study we will record their illness. That information will be treated as 
confidentially as all the other information you give us, and no-one outside this study will be able 
to find out your name or any other information that would identify you.  
 
How will I know about the results of the study? 
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At the end of the study a report will be sent to the clinic/outpatient department and to the people 
who took part in the study. 
 
Who is organising the research? 
If you need to talk to someone about this research, you can contact the this person: 
 
Dr Isiaka-Lawal Salamat, Kwara State Specialist Hospital, Sobi, Ilorin. 
08039124662.  
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APPENDIX II 
Consent form for: an exploration of symptom burden among breast and gynaecological 
cancer patients accessing care at UITH, Ilorin    
 
1. I confirm that I have read and understand the information sheet and have had the opportunity to ask 
questions. 
 
2. I understand that my participation is voluntary and I am free to withdraw at any time, without giving 
a reason, without my care being affected. 
 
 
3. I agree to take part in the above study. 
 
Name ________________________________    
 
Signature _____________________________  Date ________________ 
 
Researcher:  Signature __________________   Date: _______________   
   
Witness:  Name  
(from clinical team or family member) 
 
Signature ______________________________ Date: _________ 
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APPENDIX III 
Study ID N0______Date 1st Contact ___/___/___ Proposed 2nd Contact___/____/__ Phone____ 
 
MEMORIAL SYMPTOM ASSESSMENT SCALE – Short Form [MSAS-SF] 
 
I. INSTRUCTIONS:  Below is a list of symptoms.  If you had the symptom DURING THE PAST 
WEEK, please check Yes.  If you did have the symptom, please check the box that tells us how 
much the symptom DISTRESSED or BOTHERED you. 
 
 
 
 
Check all the symptoms 
you have had during the 
PAST WEEK.  
 
 
 
Yes 
 
[✓] 
     IF YES:  How much did it DISTRESS or 
BOTHER you? 
 
Not at         A little         Some-         Quite          Very  
  All                Bit             what            a Bit        Much 
[0.8]             [1.6]            [2.4]            [3.2]            [4.0]   
100 
 
Difficulty concentrating 
      
Pain 
      
Lack of energy 
      
Cough 
      
Changes in skin 
      
Dry mouth 
      
Nausea 
      
Feeling drowsy 
      
Numbness/tingling in hands 
and feet 
      
Difficulty sleeping 
      
Feeling bloated 
      
Problems with urination 
      
Vomiting 
      
Shortness of breath 
      
Diarrhea 
      
Sweats 
      
Mouth sores 
      
Problems with sexual interest 
or activity 
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Itching 
      
Lack of appetite 
      
Dizziness 
      
Difficulty swallowing 
      
Change in the way food 
tastes 
      
Weight loss 
      
 
 
MEMORIAL SYMPTOM ASSESSMENT SCALE – Short Form [MSAS-SF] 
 
I. INSTRUCTIONS:  Below is a list of symptoms.  If you had the symptom DURING THE PAST 
WEEK, please check Yes.  If you did have the symptom, please check the box that tells us how 
much the symptom DISTRESSED or BOTHERED you. 
 
 
 
 
 
Check all the symptoms 
you have had during the 
PAST WEEK.  
 
 
 
Yes 
 
[✓] 
     IF YES:  How much did it DISTRESS or 
BOTHER you? 
 
Not at         A little         Some-         Quite          Very  
  All                Bit             what            a Bit        Much 
   [0.8]           [1.6]            [2.4]            [3.2]          [4]   
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Hair loss 
      
Constipation       
Swelling of arms or legs       
“I don’t look like myself”       
If you had any other 
symptoms during the 
PAST WEEK, please list 
them below, and indicate 
how much the symptom 
DISTRESSED or 
BOTHERED you. 
 
1.  _____________ 
      
 
2._____________ 
      
 
II. Below are other commonly listed symptoms. Please indicate if you have had the  
symptom DURING THE PAST WEEK, and if so, how OFTEN  it occurred. 
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Check all the 
symptoms you have 
had during the 
PAST WEEK 
 
 
Yes 
 
[✓] 
         IF YES, How OFTEN  did it  occur? 
 
                                                                              Almost 
Rarely            Occasionally      Frequently       
Constantly 
   [1]                         [2]                     [3]                    [4] 
Feeling sad      
Worrying      
Feeling irritable      
Feeling nervous      
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Memorial Symptom Assessment Scale Subscales 
 The scoring of the MSAS yields several validated subscale scores.  
A 10 item MSAS Global Distress Index (MSAS-GDI) is considered to be a measure of overall 
symptom distress. The GDI is the average of the frequency of 4 prevalent psychological 
symptoms (feeling sad, worrying, feeling irritable, and feeling nervous) and the distress 
associated with 6 prevalent physical symptoms (lack of appetite, lack of energy, pain, feeling 
drowsy, constipation, dry mouth).    
The Physical Symptom Subscale score (MSAS-PHYS) is the average of the frequency, severity 
and distress associated with 12 prevalent physical symptoms: lack of appetite, lack of energy, 
pain, feeling drowsy, constipation, dry mouth, nausea, vomiting, change in taste, weight loss, 
feeling bloated, and dizziness.  
The Psychological Symptom Subscale score (MSAS-PSYCH) is the average of the frequency, 
severity and distress associated with 6 prevalent psychological symptoms: worrying, feeling sad, 
feeling nervous, difficulty sleeping, feeling irritable, and difficulty concentrating.   
The Total MSAS score (TMSAS) is the average of the symptom scores of all 32 symptoms in 
the MSAS instrument. Each symptom score is an average of its dimensions. 
In the short form, there is only one dimension for each symptom, distress for physical symptoms 
and frequency for psychological symptoms. 
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Memorial Symptom Assessment Scale Short Form Subscales 
 The scoring of the MSAS-SF  yields several validated subscale scores.  
A 10 item MSAS Global Distress Index (MSAS-GDI) is considered to be a measure of overall 
symptom distress. The GDI is the average of the frequency of 4 prevalent psychological 
symptoms (feeling sad, worrying, feeling irritable, and feeling nervous) and the distress 
associated with 6 prevalent physical symptoms (lack of appetite, lack of energy, pain, feeling 
drowsy, constipation, dry mouth).  
MSAS SF GDI = (feeling sad, worrying, feeling irritable, feeling nervous, lack of appetite, 
lack of energy, pain, feeling drowsy, constipation, dry mouth)/10 
 
 The Physical Symptom Subscale score (MSAS-PHYS) is the average of the distress 
associated with 12 prevalent physical symptoms: lack of appetite, lack of energy, pain, feeling 
drowsy, constipation, dry mouth, nausea, vomiting, change in taste, weight loss, feeling bloated, 
and dizziness. Note that the scaling is in increments of 0.8, with zero for no symptom, 0.8 for 
symptom present but no distress, and upwards for increasing levels of distress. 
MSAS SF PHYS = (lack of appetite, lack of energy, pain, feeling drowsy, constipation, dry 
mouth, nausea, vomiting, change in taste, weight loss, feeling bloated, and dizziness) / 12 
 
 The Psychological Symptom Subscale score (MSAS-PSYCH) is the average of the 
frequency associated with 6 prevalent psychological symptoms: worrying, feeling sad, feeling 
nervous, difficulty sleeping, feeling irritable, and difficulty concentrating.  Scoring is in 
increments of one, with zero for no symptom to 4 for “almost constantly”. 
MSAS SF PSYCH = (worrying, feeling sad, feeling nervous, difficulty sleeping, feeling 
irritable, and difficulty concentrating)/6 
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 The Total MSAS score (TMSAS) is the average of the symptom scores of all 32 
symptoms in the MSAS instrument.  
 In the short form, there is only one dimension for each symptom, distress for physical 
symptoms and frequency for psychological symptoms. The sequence of symptoms in the short 
form is different from that in the long form. 
Scoring of physical symptoms in the MSAS-SF is as follows: 
Zero if the symptom is not present 
0.8 if the symptom is present but causes no distress 
1.6 if the symptom is present and causes a little bit of distress 
2.4 if the symptom is present and causes somewhat of distress 
3.2 if the symptom is present and causes quite a bit of distress 
4.0 if the symptom is present and causes very much distress. 
Scoring of psychological symptoms is: 
0 if the symptom is absent 
1 if the symptom is present and occurs rarely 
2 if the symptom is present and occurs occasionally 
3 if the symptom is present and occurs frequently 
4 if the symptom is present and occurs almost constantly. 
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APPENDIX IV 
Participant Data Sheet 
Date :___________Where seen: _______________ Study N0__________  Phone 
N0_________________ 
Age:________                   Occupation______________________________ 
Educational  level:     a) None          b) primary        c) secondary            d) tertiary 
Religion:______________________________________________ 
Ethnicity:  a)Yoruba         b) Hausa         c) Igbo         d) Others________________________  
Duration of illness: _____________________________  
Diagnosis:_____________________       Diagnosis confirmed by histology:  Yes(  ) No(   ) 
Stage documented:___________________          Stage not documented: (    ) Tick  
Indication for present admission (inpatients 
only):________________________________________ 
Previous cancer specific treatment (if applicable): Tick all that apply. 
i. Chemotherapy                                       iv. Hormonal therapy 
ii. Surgery                                                    v. None     
iii. Radiotherapy                                   
Current cancer specific treatment:____________________________________ 
Number of Courses of treatment (Chemotherapy/Radiotherapy)__________________ 
Status of treatment : Ongoing/ Abandoned/Completed/Interrupted/Others 
(specify)_______________ 
Remarks______________________________________________________________________
________ 
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Involvement of hospital palliative care unit in management:  Yes/No 
Present drug management (both cancer specific and non-cancer specific) 
1. _____________________________         5._________________________ 
2. -----------------------------------------------         6_________________________   
3. ----------------------------------------------           7__________________________ 
4. -------------------------------------------------      8___________________________ 
    Present nondrug management (physiotherapy, music therapy, massage etc) 
1. ----------------------------------------- 
2. ---------------------------------------. 
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APPENDIX V 
Karnofsky performance scale: 
100    Able to carry on normal activity; no special care needed. Normal, no complaints, no 
evidence of disease. 
 
90 Able to carry on normal activity, minor signs or symptoms of disease 
 
80 Normal activity with effort. some signs or symptoms of disease 
   
70 Cares for self, unable to carry on normal activity or to do active work 
   
60   Requires occasional assistance from others but able to care for most of his needs 
 
50   Requires considerable assistance from others and frequent medical care. 
 
40   Disabled, requires special care and assistance. 
 
30   Severely disabled, hospitalization indicated, death not imminent  
  
20 Very sick, hospitalization necessary, active supportive treatment necessary. 
   
10  Moribound  , disease may be rapidly progressing. 
 
0    Dead. 
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APPENDIX VI 
                                                                             Department of Obstetrics and Gynaecology, 
                                                                             Kwara State Specialist Hospital, Sobi, Ilorin.  
                                                                             19th October, 2015 
 
The Head of Department, 
Department of Surgery,                                          
University of Ilorin Teaching Hospital, 
Ilorin.                   
         
 
Dear HOD, 
 
LETTER OF PERMISSION 
 
I am writing to invite patients with breast/gynaecological cancer to participate in my research. 
I am studying Palliative Medicine at the University of Cape Town, South Africa.  
This research is in partial fulfilment towards the award of Masters Degree in Palliative Medicine. 
 
The study is a descriptive, comparative, cross sectional study exploring the symptom burden and 
relief of these symptoms among these groups of patients.  
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I will be using the Memorial Symptom Assessment Scale-Short Form (MSAS-SF) which is a 
symptom assessment tool, to assess patient symptoms and the degree to which the symptoms 
cause distress. I will also be using a questionnaire to obtain other information from the patients 
as well as from the case notes. I will be working with one research assistant.   
 
I will introduce the research study to your staff. The research assistant will be fully trained and 
knowledgeable regarding the approved protocol. This study will not be beginning until we have 
full ethical approval.  
 
I am writing to outline some basic study information.  
 
• Who are we recruiting? 
We are recruiting a total of 100 adult patients with breast or gynaecologic cancer. The patients 
will be those accessing care at the University of Ilorin Teaching Hospital.  
 
• How will patients be approached to ask them if they want to take part?  
We ask that your staff identify patients who meet the criteria, and then explain that we are 
recruiting to a study using questionnaires that ask about their health that would last about 15-
20 minutes. If patients are interested in taking part a researcher will speak to them and give 
further information. If they agree to take part, the researcher will ask for informed consent. 
The study is entitled ‘’an exploration of symptom burden in breast and gynaecological cancer 
patients accessing care at University of Ilorin Teaching Hospital’’. The questionnaire is a 
composite one with 4 parts: A validated tool called Memorial Symptom Assessment Scale, a 
table to document symptoms relieved/not relieved and the degree of relief, the third part that 
would document information extracted from the case notes and the fourth part that involves 
repeat of the Memorial Symptom Assessment Scale after a week’s interval.   
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• How will data collection happen? 
The researcher will then conduct the interview if the patient has given consent. The researcher 
will hold and store the data in a locked store and will keep the personal information (e.g. name) 
separate from the questionnaire data. The patient’s name will not appear on the questionnaire 
which will only have a study number as an identifier. 
 
• What if a patient becomes distressed?  
All respondents will have the opportunity to halt the interview at any time, and will have 
debriefing (i.e. time to talk without data being collected) at the end of the interview. If the 
researcher is concerned about respondent distress, they will inform one of the clinical team and 
will let the patient know that they are doing so.  
 
• What are the responsibilities of the study site? 
We are asking you to assist in identifying patients who meet the study criteria and to introduce 
them to the researcher who will discuss the research with them and ask for their informed 
consent.  
We are also asking that should a patient become distressed during the interview that your 
counselling staff would be prepared to provide the necessary support for the participant. We have 
found in previous studies that participants welcome the opportunity to respond to questions 
asked in the Patient Outcome Score and that distress is infrequent. Please would you note your 
agreement to provide this support when you respond to our request to conduct research within 
your facility. If you do not have the resources to provide counselling support, we will identify a 
counsellor who can be on call if required, should a participant express distress or should the 
researcher identify possible distress.  
 
• What about study feedback? 
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We will liaise closely with you to let you know the number of interviews complete and the 
remaining interviews needed. We will also produce a dissemination brief on the findings for 
display within your service, and this will be written in lay language.  
 
We look forward to working with you and fixing the date for launch once we have full ethical 
approval and translated materials.  
 
Please don’t hesitate to contact me should you require further information in the meantime. I will 
remain the Principal Investigator throughout the study, and encourage you to raise any thoughts 
with my research assistant or with me. You may raise any ethical concerns with the UITH ERC.  
 
 
Yours sincerely, 
Dr Isiaka-Lawal Salamat. 
Salamat.lawal@gmail.com 
08039124662 
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                                                                             Department of Obstetrics and Gynaecology, 
                                                                             Kwara State Specialist Hospital, Sobi, Ilorin.  
                                                                             19th October, 2015 
 
The Head of Department, 
Department of Obstetrics & Gynaecology,                                      
University of Ilorin Teaching Hospital, 
Ilorin.                   
         
 
Dear HOD, 
 
LETTER OF PERMISSION 
 
I am writing to invite patients with breast/gynaecological cancer to participate in my research. 
I am studying Palliative Medicine at the University of Cape Town, South Africa.  
This research is in partial fulfilment towards the award of Masters Degree in Palliative Medicine. 
 
The study is a descriptive, comparative, cross sectional study exploring the symptom burden and 
relief of these symptoms among these groups of patients.  
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I will be using the Memorial Symptom Assessment Scale-Short Form (MSAS-SF) which is a 
symptom assessment tool, to assess patient symptoms and the degree to which the symptoms 
cause distress. I will also be using a questionnaire to obtain other information from the patients 
as well as from the case notes. I will be working with one research assistant.   
 
I will introduce the research study to your staff. The research assistant will be fully trained and 
knowledgeable regarding the approved protocol. This study will not be beginning until we have 
full ethical approval.  
 
I am writing to outline some basic study information.  
 
• Who are we recruiting? 
We are recruiting a total of 100 adult patients with breast or gynaecologic cancer. The patients 
will be those accessing care at the University of Ilorin Teaching Hospital.  
 
• How will patients be approached to ask them if they want to take part?  
We ask that your staff identify patients who meet the criteria, and then explain that we are 
recruiting to a study using questionnaires that ask about their health that would last about 15-
20 minutes. If patients are interested in taking part a researcher will speak to them and give 
further information. If they agree to take part, the researcher will ask for informed consent. 
The study is entitled ‘’an exploration of symptom burden in breast and gynaecological cancer 
patients accessing care at University of Ilorin Teaching Hospital’’. The questionnaire is a 
composite one with 4 parts: A validated tool called Memorial Symptom Assessment Scale, a 
table to document symptoms relieved/not relieved and the degree of relief, the third part that 
would document information extracted from the case notes and the fourth part that involves 
repeat of the Memorial Symptom Assessment Scale after a week’s interval.   
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• How will data collection happen? 
The researcher will then conduct the interview if the patient has given consent. The researcher 
will hold and store the data in a locked store and will keep the personal information (e.g. name) 
separate from the questionnaire data. The patient’s name will not appear on the questionnaire 
which will only have a study number as an identifier. 
 
• What if a patient becomes distressed?  
All respondents will have the opportunity to halt the interview at any time, and will have 
debriefing (i.e. time to talk without data being collected) at the end of the interview. If the 
researcher is concerned about respondent distress, they will inform one of the clinical team and 
will let the patient know that they are doing so.  
 
• What are the responsibilities of the study site? 
We are asking you to assist in identifying patients who meet the study criteria and to introduce 
them to the researcher who will discuss the research with them and ask for their informed 
consent.  
We are also asking that should a patient become distressed during the interview that your 
counselling staff would be prepared to provide the necessary support for the participant. We have 
found in previous studies that participants welcome the opportunity to respond to questions 
asked in the Patient Outcome Score and that distress is infrequent. Please would you note your 
agreement to provide this support when you respond to our request to conduct research within 
your facility. If you do not have the resources to provide counselling support, we will identify a 
counsellor who can be on call if required, should a participant express distress or should the 
researcher identify possible distress.  
 
• What about study feedback? 
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We will liaise closely with you to let you know the number of interviews complete and the 
remaining interviews needed. We will also produce a dissemination brief on the findings for 
display within your service, and this will be written in lay language.  
 
We look forward to working with you and fixing the date for launch once we have full ethical 
approval and translated materials.  
Please don’t hesitate to contact me should you require further information in the meantime. I will 
remain the Principal Investigator throughout the study, and encourage you to raise any thoughts 
with my research assistant or with me. You may raise any ethical concerns with the UITH ERC.  
 
Yours sincerely, 
Dr Isiaka-Lawal Salamat. 
Salamat.lawal@gmail.com 
08039124662 
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